0000799698-17-000023.txt : 20170803 0000799698-17-000023.hdr.sgml : 20170803 20170802205043 ACCESSION NUMBER: 0000799698-17-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170803 DATE AS OF CHANGE: 20170802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15327 FILM NUMBER: 171001875 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 10-Q 1 form10q-2q17.htm QUARTERLY REPORT FOR QUARTER ENDING JUNE 30, 2017 ON FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

R	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

£	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-15327

CytRx Corporation

(Exact name of Registrant as specified in its charter)

Delaware	58-1642740
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

11726 San Vicente Blvd., Suite 650 Los Angeles, CA	90049
(Address of principal executive offices)	(Zip Code)

(310) 826-5648

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes R No £

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes R No £

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer £	Accelerated filer R
Non-accelerated filer £	(Do not check if a smaller reporting company)
	Smaller reporting company £
	Emerging growth company £

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. £

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes £ No R

Number of shares of CytRx Corporation common stock, $0.001 par value, outstanding as of August 3, 2017: 165,710,526 shares.

CYTRX CORPORATION

FORM 10-Q

TABLE OF CONTENTS

	Page
PART I. — FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3. Quantitative and Qualitative Disclosures About Market Risk	18
Item 4. Controls and Procedures	19

PART II. — OTHER INFORMATION
Item 1. Legal Proceedings	20
Item 6. Exhibits	20

SIGNATURES	21

INDEX TO EXHIBITS	22

PART I — FINANCIAL INFORMATION

Item 1. — Financial Statements

CYTRX CORPORATION
CONDENSED BALANCE SHEETS
(Unaudited)

	June 30, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	54,972,846		$	56,959,485
Receivables		47,631			183,703
Prepaid expenses and other current assets		1,782,141			3,434,238
Total current assets		56,802,618			60,577,426
Equipment and furnishings, net		1,323,579			1,959,667
Goodwill		183,780			183,780
Other assets		38,014			48,911
Total assets	$	58,347,991		$	62,769,784
LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities: Accounts payable	$	7,080,080		$	6,406,445
Accrued expenses and other current liabilities		2,972,082			3,830,498
Warrant liabilities		6,567,080			3,789,391
Term loan, net - current		6,701,040			5,481,656
Total current liabilities		23,320,282			19,507,990

Long term loan, net		15,813,507			18,484,510
Total liabilities		39,133,789			37,992,500
Commitments and contingencies

Stockholders' equity:
Preferred Stock, $0.01 par value, 5,000,000 shares authorized, including 25,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding		—			—
Preferred Stock, $1,000 stated value, 3,900 shares authorized, 0 and 3,108 outstanding at June 30, 2017 and December 31, 2016		—			3,108,000
Common stock, $0.001 par value, 250,000,000 shares authorized; 153,127,389 shares issued and outstanding at June 30, 2017; 111,322,895 shares issued and outstanding at December 31, 2016		153,126			111,321
Additional paid-in capital		460,329,472			437,423,958
Accumulated deficit		(441,268,396	)		(415,865,995	)
Total stockholders' equity		19,214,202			24,777,284
Total liabilities and stockholders' equity	$	58,347,991		$	62,769,784

The accompanying notes are an integral part of these condensed financial statements.

CYTRX CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue:
License revenue	$	—		$	100,000		$	—		$	100,000

Expenses:
Research and development		6,167,074			12,452,340			12,934,058			20,604,559
General and administrative		3,137,008			6,128,904			6,116,063			10,087,340
		9,304,082			18,581,244			19,050,121			30,691,899

Loss before other income (loss)		(9,304,082	)		(18,481,244	)		(19,050,121	)		(30,591,899	)

Other income (loss):
Interest income		90,849			65,436			151,392			127,174
Interest expense		(848,395	)		(741,346	)		(2,171,110	)		(1,158,148	)
Other income (loss), net		7,276			(798	)		3,504			6,081
Gain (loss) on warrant derivative liabilities		(4,303,945	)		877,729			(4,336,066	)		693,457

Net loss	$	(14,358,297	)	$	(18,280,223	)	$	(25,402,401	)	$	(30,923,335	)

Basic and diluted net loss per share	$	(0.10	)	$	(0.27	)	$	(0.20	)	$	(0.46	)

Basic and diluted weighted-average shares outstanding		139,070,329			67,398,837			126,394,244			66,893,846

The accompanying notes are an integral part of these condensed financial statements

CYTRX CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended June 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(25,402,401	)	$	(30,923,335	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		348,843			213,964
Stock-based compensation expense		1,731,484			4,364,886
Fair value adjustment on warrant liabilities		4,336,066			(693,457	)
Non-cash litigation settlement due in common stock		—			700,000
Amortization of loan cost and discount		975,743			208,148
Loss on retirement of fixed assets		421,843			3,388
Changes in assets and liabilities:
Receivables		136,072			4,368,773
Interest receivable		—			28,130
Prepaid expenses and other current assets		1,662,994			1,432,127
Accounts payable		673,635			(844,373	)
Accrued expenses and other current liabilities		(1,026,781	)		(4,297,864	)
Net cash used in operating activities		(16,142,502	)		(25,439,613	)

Cash flows from investing activities:
Proceeds from the sale of short-term investments		—			35,035,420
Purchases of equipment and furnishings		(134,598	)		(660,758	)
Net cash provided by (used in) investing activities		(134,598	)		34,374,662

Cash flows from financing activities:
Proceeds from public offering		13,951,218			—
Proceeds from term loan, net		—			24,012,078
Payment of principal on term loan		(2,427,362	)		—
Net proceeds from exercise of warrants and stock options		2,766,605			704,700
Net cash provided by financing activities		14,290,461			24,716,778

Net increase (decrease) in cash and cash equivalents		(1,986,639	)		33,651,827
Cash and cash equivalents at beginning of period		56,959,485			22,261,372
Cash and cash equivalents at end of period	$	54,972,846		$	55,913,199

Supplemental disclosure of cash flow information:

Cash paid during the year for interest	$	1,212,219		$	752,083

Cash paid for income taxes	$	800		$	800

Supplemental disclosure of non-cash activties:

Warrant liability exercise	$	1,558,377	$	—

Preferred stock conversion	$	7,400	$	—

Warrants issued in connection with term loan	$	—	$	633,749

Equipment and furnishings purchased on credit	$	—	$	79,247

Shares issued in connection with the class action settlement	$	—	$	4,500,000

The accompanying notes are an integral part of these condensed financial statements.

NOTES TO CONDENSED FINANCIAL STATEMENTS

June 30, 2017
(Unaudited)

1. Description of Company and Basis of Presentation

CytRx Corporation ("we," "us," "our," CytRx" or the "company") is a biopharmaceutical company specializing in oncology. Our focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, our lead clinical candidate, has been tested in over 600 patients with various types of cancer.

CytRx's lead product candidate is aldoxorubicin, a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor. Specifically, it is comprised of (6-maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Our lead indication for aldoxorubicin is for patients with advanced soft tissue sarcomas (STS). We met with the FDA in March 2017 to discuss a regulatory pathway for a New Drug Application (NDA) for aldoxorubicin in STS.

Aldoxorubicin has received Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of STS. ODD provides several benefits including seven years of market exclusivity after approval, certain R&D related tax credits, and protocol assistance by the FDA. European regulators granted aldoxorubicin Orphan designation for STS which confers ten years of market exclusivity among other benefits.

On July 27, 2017, CytRx entered into an exclusive worldwide license with NantCell, Inc. ("NantCell"), granting them rights to develop, manufacture and commercialize aldoxorubicin in all indications. As part of the license, NantCell made a strategic investment of $13 million in CytRx common stock $1.10 per share, a premium of 92% to the market price on that date. CytRx is entitled to receive up to $343 million in milestones related to regulatory approvals and commercial milestones. CytRx is entitled to receive ascending double-digit royalties for net sales for soft tissue sarcomas and mid to high single digit royalties for other indications. NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin including the cost of filing the NDA.

CytRx has an active drug discovery and research operation at our laboratory facilities in Freiburg, Germany, focusing on the creation of novel drug anti-cancer candidates by combining our proprietary linker technologies with ultra-high potency cytotoxic drugs. We are expanding our pipeline of ultra-high potency oncology candidates through our LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and next generation linker technologies for the development of a new class of potential breakthrough anti-cancer therapies.

We have created a "toolbox" of linker technologies that have the ability to significantly increase the therapeutic index of ultra-high potency drugs (10-1,000 times more potent than traditional chemotherapies) by controlling the release of the drug payloads and improving drug-like properties. After infusion, these ultra-high potency drug conjugates bind to circulating albumin for transport of the drug to the tumor. Subsequently, due to specific conditions within the tumor, the linkers are cleaved and release the anti-cancer drug payload.

Our current efforts are focused on two classes of ultra-high potency drug conjugates. Our strategy across these programs is to generate additional pre-clinical data that will allow us to make informed decisions regarding the selection of one or both programs for moving into human clinical trials either independently or on a partnered basis.

The accompanying condensed financial statements at June 30, 2017 and for the three-month and six-month periods ended June 30, 2017 and 2016, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2016 have been derived from the our audited financial statements as of that date.

The financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company's audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2016.

As a result of the worldwide license of all of our rights to aldoxorubicin to NantCell, NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin, thereby enabling us to eliminate our future research and development activities related to aldoxorubicin. Currently, our only research and development activities are conducted by our Freiburg, Germany, laboratory facility. For this reason and others, our operating expenses are expected to be significantly lower in the near future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

2. Foreign Currency Remeasurement

The U.S. dollar has been determined to be the functional currency for the net assets of our German laboratory facilty. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a gain of approximately $6,200 and $1,300, respectively, for the three-month and six-month periods ended June 30, 2017 and a gain of approximately $600 and $5,800, respectively, for the three and six-month periods ended June 30, 2016, respectively. The Company does not engage in currency hedging transactions.

3. Recent Accounting Pronouncements

In January 2017, the FASB issued updated guidance to clarify the definition of a business within the context of business combinations. The updated guidance requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This updated guidance is expected to reduce the number of transactions that need to be further evaluated as business combinations. If further evaluation is necessary, the updated guidance will require that a business set include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output. The updated guidance will remove the evaluation of whether a market participant could replace missing elements. The new guidance is effective for annual and interim periods beginning after December 15, 2017 and is to be applied on a prospective basis. We are currently evaluating the new guidance.

In January 2017, the FASB issued updated guidance which eliminated Step 2 from the goodwill impairment test. Step 2 is the process of measuring a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires entities to measure a goodwill impairment loss as the amount by which a reporting unit's carrying value exceeds its fair value, limited to the carrying amount of goodwill. The FASB also eliminated the requirements for entities that have reporting units with zero or negative carrying amounts to perform a qualitiative assessment for the goodwill impairment test. Instead, those entities would be required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount. The new guidance is effective for intrerim or annual goodwill impairment tests performed in fiscal years beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the new guidance.

In March 2016, the FASB issued Accounting Standards Update 2016-09, Compensation—Stock Compensation ("ASU 2016-09"). ASU 2016-09 includes several areas of simplification to stock compensation including simplifications to the accounting for income taxes, classification of excess tax benefits on the Statement of Cash Flows and forfeitures. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016. We adopted this Standard on January 1, 2017. The adoption of this Standard did not have material impact to the Company's financial position or its results of operations.

In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 allows the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The Update 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and early adoption is permitted. We are still evaluating the effect of this update.

In January 2016, the FASB issued Accounting Standards Update 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). ASU 2016-01 eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. The standard also clarifies the need to evaluate a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with our other deferred tax assets. The update 2016-01 is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

4. Term Loan

On February 5, 2016, we entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. ("HTGC"), as administrative agent and lender, and Hercules Technology III, L.P., as lender ("Hercules"), pursuant to which the lenders made term loans to us on February 8, 2016 in the aggregate principal amount of $25 million (the "Term Loans").

The Term Loans bear interest at the daily variable rate per annum equal to 6.0% plus the prime rate, or 10.25%, whichever is greater. We are required to make interest-only payments on the Term Loans through February 28, 2017, and beginning on March 1, 2017 blended equal monthly installments of principal amortization and accrued interest until the maturity date of the Term Loans on February 1, 2020. Under the terms of the loan, we are required to maintain a minimum cash balance equal to the greater of (i) $10 million or (ii) forward three months projected cash burn. As security under our obligations, we issued to the lenders warrants to purchase a total of 634,146 shares of our common stock at an exercise price of $2.05. These warrants are classified as equity warrants with a fair value of $633,749. All outstanding principal and accrued interest on the term loans will be due and payable in full on the maturity date of February 1, 2020.

As security for our obligations under the loan and securities agreement, we granted HTGC, as administrative agent, a security interest in substantially all of our existing and after-acquired assets except for our intellectual property and certain other excluded assets. The loan and security agreement contains customary representations, warranties and covenants.

	June 30, 2017			December 31, 2016
Term Loan Principal – Current	$	7,737,492		$	6,214,057
Issuance Cost/Loan Discount – Current		(1,036,452	)		(732,401	)
Term Loan, Net – Current	$	6,701,040		$	5,481,656

Long Term Loan Principal	$	14,835,146		$	18,785,943
End Fee Payable		1,771,250			1,771,250
Long Term Loan Discount/Issuance Cost		(792,889	)		(2,072,683	)
Long Term Loan, Net	$	15,813,507		$	18,484,510

On July 28, 2017, we entererd into an Amended Loan Services Agreement with the lenders of the Term Loans whereby we agreed to make an immediate payment of $5 million of principal and unpaid interest, a further $5 million payment of principal and unpaid interest by September 30, 2017, and agreed to an updated schedule of monthly payments and a new maturity date of August 1, 2018.

The interest expense on the loan for the three-month and six-month periods ended June 30, 2017 was $848,395 and $2,171,110, respectively, as compared to $741,346 and $1,158,148 for comparative 2016 periods.

5. Basic and Diluted Net Loss Per Common Share

Basic and diluted net loss per common share is computed based on the weighted-average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per common share where the effect would be anti-dilutive. Common share equivalents that could potentially dilute net loss per share in the future, and which were excluded from the computation of diluted loss per share, totaled 44.8 million shares for each of the three-month and six-month periods ended June 30, 2017, and 22.4 million shares for each of the three-month and six-month periods ended June 30, 2016.

6. Warrant Liabilities

Liabilities measured at fair value on a recurring basis include warrant liabilities resulting from our equity financings. In accordance with ASC 815-40, Derivatives and Hedging – Contracts in Entity's Own Equity ("ASC 815-40"), the warrant liabilities are recorded at fair value until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with the Company's application of ASC 505-50, Equity-Based Payments to Non-Employees ("ASC 505-50"). The gain or loss resulting from the change in fair value is shown on the Condensed Statements of Operations as gain (loss) on warrant derivative liability. We recognized a loss of $4.3 million and a gain of $0.9 million for the three-month periods ended June 30, 2017 and 2016, respectively, and a loss of $4.3 million and a gain of $0.7 million for the six-month periods ended June 30, 2017 and 2016, respectively. The following reflects the weighted-average assumptions for each of the six-month periods indicated:

	Six Months Ended June 30,
	2017			2016

Risk-free interest rate		1.13	%		0.20	%
Expected dividend yield		0	%		0	%
Expected lives		0.79			0.09
Expected volatility		125.3	%		59.3	%
Warrants classified as liabilities (in shares)		24,110,577			6,371,854

Our computation of expected volatility is based on the historical daily volatility of our publicly traded stock. The dividend yield assumption of zero is based upon the fact that we have never paid cash dividends and presently have no intention to do so. The risk-free interest rate used for each warrant classified as a derivative is equal to the U.S. Treasury rates in effect at June 30 of each year presented. The expected lives are based on the remaining contractual lives of the related warrants at the valuation date.

On July 19, 2017, 6,340,148 warrants expired.

7. Stock Based Compensation

We have a 2000 Long-Term Incentive Plan, which expired on August 6, 2010. As of June 30, 2017, there were approximately 0.4 million shares subject to outstanding stock options under this plan. No further shares are available for future grant under this plan.

We also have a 2008 Stock Incentive Plan. As of June 30, 2017, there were 16.4 million shares subject to outstanding stock options and 2.5 million shares outstanding related to restricted stock grants options and 10.4 million shares available for future grant under this plan.

We follow ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.

For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50.

Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. As a result, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Statements of Operations:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development — employee	$	278,533	$	507,195	$	631,616	$	988,006
General and administrative — employee		401,820		2,499,368		869,485		3,156,418
Total employee stock-based compensation	$	680,353	$	3,006,563	$	1,501,101	$	4,144,424

Research and development — non-employee	$	—	$	—	$	—	$	—
General and administrative — non-employee		36,578		32,506		65,237		220,462
Total non-employee stock-based compensation	$	36,578	$	32,506	$	65,237	$	220,462

During the six-month period ended June 30, 2017, we granted stock options to purchase 10,000 shares of our common stock at an average weighted exercise price of $0.41. During the six-month period ended June 30, 2016, we granted stock options to purchase 425,000 shares of our common stock and warrants to purchase 500,000 shares of our common stock at a weighted average exercise price of $1.74. In the three-month period ended June 30, 2016, we amended the terms of stock options of a former executive in respect of a Retirement Agreement, resulting in a one-time expense of approximately $1.9 million. The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	Six Months Ended June 30, 2017			Six Months Ended June 30, 2016
Risk-free interest rate		2.04	%		1.47	%
Expected volatility		85.5	%		76.3	%
Expected lives (years)		6			5 - 10
Expected dividend yield		0.00	%		0.00	%

Our computation of expected volatility is based on the historical daily volatility of our publicly traded stock. We use historical information to compute expected lives. In the six-month period ended June 30, 2017, the contractual term of the options granted was ten years. The dividend yield assumption of zero is based upon the fact we have never paid cash dividends and presently have no intention to do so. The risk-free interest rate used for each grant and issuance is equal to the U.S. Treasury rates in effect at the time of the grant and issuance for instruments with a similar expected life. Based on historical experience, for the six-month period ended June 30, 2016, we estimated annualized forfeiture rates of 10% for options granted to our employees, 2% for options granted to senior management and 0% for options granted to directors and non-employees and for warrants issued to non-employees Compensation costs will be adjusted for future changes in estimated forfeitures. We will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. On January 1, 2017, we adopted ASU 2016-09 and made a policy election to recognize forfeitures as they occur. The adoption of ASU 2016-09 did not have a material impact to the Company's financial condition or results of operations. No amounts relating to stock-based compensation have been capitalized.

As of June 30, 2017, there remained approximately $2.4 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors, to be recognized as expense over a weighted-average period of 1.01 years. Presented below is our stock option activity:

	Six Months Ended June 30, 2017
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2017		16,879,770			600,000		17,479,770		$	2.37
Granted		10,000			—		10,000		$	0.41
Exercised, Forfeited or Expired		(646,847	)		—		(646,847	)	$	3.16
Outstanding at June 30, 2017		16,242,923			600,000		16,842,932		$	2.34
Options exercisable at June 30, 2017		11,655,168			600,000		12,255,168		$	2.75

The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2017:

Range of Exercise Prices		Total Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Total Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$	0.41 - $1.50		4,317,533		9.45	$	0.44		1,586,461		9.46	$	0.44
$	1.51 – $2.50		8,669,296		7.32	$	2.26		6,835,946		7.07	$	2.22
$	2.51 – $4.00		960,670		6.64	$	2.88		937,337		6.61	$	2.87
$	4.01 – $32.55		2,895,424		5.69	$	5.24		2,895,424		5.69	$	5.24
			16,842,923		7.55	$	2.34		12,255,168		7.02	$	2.75

The aggregate intrinsic value of all outstanding options and vested options as of June 30, 2017 was $0.8 million and $0.3 million, respectively, representing options with exercise prices of less than the closing fair market value of our common stock on June 30, 2017 of $0.63 per share.

There were 27,989,723 and 32,502,790 warrants outstanding at June 30, 2017 and December 31, 2016, respectively both at a weighted-average exercise price of $0.68.

Restricted Stock

In December 2016, the Company granted to our Chairman and Chief Executive Officer, 2,325,581 shares of restricted common stock, pursuant to the 2008 Plan. This restricted stock vests in equal annual instalments over three years. The fair value of the restricted stock is based on the market price of the Company's shares on the grant date less the par value received as consideration. The fair value of the restricted stock on the grant date was $1,000,000. The Company recorded an employee stock-based compensation expense for restricted stock of approximately $83,029 and $165,146 respectively, for the three and six-month periods ended June 30, 2017 as compared to zero for the comparative 2016 periods.

8. Fair Value Measurements

Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management's best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	53,485	$	—	$	—		$	53,485
Warrant liabilities		—		—		(6,567	)		(6,567	)

The following table summarizes fair value measurements by level at December 31, 2016 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	56,276	$	—	$	—		$	56,276
Warrant liabilities		—		—		(3,789	)		(3,789	)

Liabilities measured at market value on a recurring basis include warrant liabilities resulting from recent debt and equity financings. In accordance with ASC 815-40, the warrant liabilities are marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with our application of ASC 505-50. The $2.8 million increase in fair value of the warrant liabilities is due to the significant excess of the exercise price over the Company's stock price as of June 30, 2017 and the close proximity to the expiration date of the warrants (see Note 6).

We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.

Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. Our non-financial assets were not material at June 30, 2017 or 2016.

9. Liquidity and Capital Resources

At June 30, 2017, we had cash and cash equivalents of approximately $55.0 million. On July 27, 2017, we entered into a global strategic licensing agreement with NantCell Inc ("NantCell") for the exclusive rights to develop, manufacture and commercialize aldoxorbuicin for all indications. Under the terms of this Agreement, NantCell made a strategic investment into our Company by purchasing $13 million of our common stock. Concurrently, we announced the signing of an amendment to the Loan Services Agreement with Hercules whereby we made an immediate principal repayment of $5 million, a further $5 million repayment by September 30, 2017, and an updated schedule of monthly instalments with a new Term Loan maturity date of August 1, 2018. Under the NantCell license, NantCell agreed to assume all future costs of developing and commercializing aldoxorubicin. Management believes that our current cash and cash equivalents, along with the net proceeds of the common stock purchase (See Note 13), will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2017 and the first seven months of 2018 of approximately $35.6 million, which includes approximately $4.7 million for our clinical programs for aldoxorubicin, approximately $3.7 million for the research and clinical development of novel anti-cancer drug candidates at our Freiburg operations, approximately $1.1 million for general operation of our clinical programs, approximately $9.4 million for other general and administrative expenses, and approximately $16.6 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If our licensing partner obtains marketing approval and successfully commercializes aldoxorubicin, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible other strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company.

10. Equity Transactions

In the first quarter of 2017, there were 3,108 shares of our outstanding Series B Convertible Preferred converted by the holders into 7.4 million shares of our common stock.

In the second quarter of 2017, there were 4,404,494 shares of our common stock issued from the exercise of warrants.

On May 2, 2017, we issued 30.0 million shares of our common stock in a public offering.

As of June 30, 2017, we have reserved approximately 10.4 million of our authorized but unissued shares of common stock for future issuance pursuant to our employee stock option plans issued to employees and consultants.

11. Income Taxes

At December 31, 2016, we had federal and state net operating loss carryforwards as of $339.0 million and $224.0 million, respectively, available to offset against future taxable income, which expire in 2017 through 2036, of which $152.0 million and $145.0 million, respectively, are not subject to limitation under Section 382 of the Internal Revenue Code.

12. Commitments and contingencies

Commitments

We have an agreement with KTB Tumorforschungs GmbH, or KTB, for the Company's exclusive license of patent rights held by KTB for the worldwide development and commercialization of aldoxorubicin. Under the agreement, we must make payments to KTB in the aggregate of $6.0 million upon meeting clinical and regulatory milestones up to and including the product's second final marketing approval. We also have agreed to pay:

·	commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);

·	a percentage of non-royalty sub-licensing income (as defined in the agreement); and

·	milestones of $1 million for each additional final marketing approval that we obtain.

In the event that we must pay a third party in order to exercise our right to the intellectual property under the agreement, we will deduct a percentage of those payments from the royalties due KTB, up to an agreed upon cap. As a result of the NantCell license and the sale of $13 million of our shares to NantCell, we will incur an obligation to pay KTB approximately $0.6 million.

Contingencies

We applied the disclosure provisions of ASC 460, Guarantees ("ASC 460") to our agreements that contain guarantees or indemnities by us. We provide (i) indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims; and (ii) indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us.

Shareholder Derivative Actions in Delaware. There are two competing derivative complaints pending in the Delaware Court of Chancery alleging claims related to our alleged retention of DreamTeamGroup and MissionIR. On December 14, 2015, a shareholder derivative complaint, captioned Niedermeyer et al. v. Kriegsman et al., C.A. No. 11800, was filed against certain of our officers and directors, for which a second amended complaint was filed on October 12, 2016. On September 6, 2016, one of the plaintiffs in the California litigation (discussed above) effectively refiled his complaint in the Delaware Court of Chancery, with the case captioned Taylor v. Kriegsman, C.A. No. 12720. Following competing motions for appointment of a lead plaintiff and lead counsel, On February 22, 2017, the Court of Chancery appointed Niedermeyer et al.as lead plaintiffs in the complaint. On May 3, 2017, the parties entered into negotiations with a mediator and on June 2, 2017, the parties entered into a Memorandum of Understanding ("MOU") to settle the entire action. On June 15, 2017, the MOU was submitted to the Court.

Class Action in California. On July 25 and 29, 2016, nearly identical class action complaints were filed in the U.S. District Court for the Central District of California, titled Crihfield v. CytRx Corp., et al., Case No. 2:16-cv-05519 and Dorce v. CytRx Corp., Case No. 2:16-cv-05666 alleging that we and certain of our officers violated the Securities Exchange Act of 1934 by allegedly making materially false and/or misleading statements, and/or failing to disclose material adverse facts to the effect that the clinical hold placed on the Phase 3 trial of aldoxorubicin for STS would prevent sufficient follow-up for patients involved in the study, thus requiring further analysis, which could cause the trial's results and/or FDA approval to be materially adversely affected or delayed. The plaintiffs allege that such wrongful acts and omissions caused significant losses and damages to a class of persons and entities that acquired our securities between November 18, 2014 and July 11, 2016, and seek an award of compensatory damages, costs and expenses, including counsel and expert fees, and such other and further relief as the Court may deem just and proper. On October 26, 2016, the Court entered an Order consolidating the actions titled In re: CytRx Corporation Securities Litigation, Master File No. 16-cv-05519-SJO and appointing a Lead Plaintiff and Lead Counsel. Following the filing of a first amended complaint on January 13, 2017, on March 14, 2017 the Company and the individual defendants filed a Motion to Dismiss. Plaintiff filed an Opposition thereto on April 28, 2017. The Company and the individual defendants filed a Reply on May 30, 2017 and the matter was heard by the Court on June 12, 2017. On June 14, 2017, the Court issued an Order granting the Motion to Dismiss with leave to amend. Plaintiff filed a Second Amended Complaint and the Individual Defendants filed a renewed Motion to Dismiss. Plaintiff filed an Opposition thereto on July 24, 2017. The Company and the Individual Defendants filed a Reply on July 31, 2017 and the matter is set to be heard by the Court on August 14, 2017.

The Company intends to vigorously defend against the foregoing complaints. CytRx has directors' and officers' liability insurance, which will be utilized in the defense of these matters. The liability insurance may not cover all of the future liabilities the Company may incur in connection with the foregoing matters. These claims are subject to inherent uncertainties, and management's view of these matters may change in the future.

The Company evaluates developments in legal proceedings and other matters on a quarterly basis. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company has accrued $0.7 million of litigation settlement related to Shareholder Derivative actions.

We evaluate developments in legal proceedings and other matters on a quarterly basis. If an unfavorable outcome becomes probable and reasonably estimable, we could incur charges that could have a material adverse impact on our financial condition and results of operations for the period in which the outcome becomes probable and reasonably estimable.

13. Subsequent Events

On July 27, 2017, we entered into a global strategic license agreement (the "License Agreement") with NantCell, Inc. ("NantCell"), for providing NantCell the exclusive rights to develop and commercialize aldoxorubicin for all indications. Under the terms of the License Agreement, CytRx is entitled to receive up to $343 million in milestone payments related to regulatory approvals and commercial milestones for aldoxorubicin. In addition, CytRx will receive certain specified royalties for all other indications (our receipt of which would obligate us to make certain payments to KTB). NantCell will be responsible for all future development, manufacturing and commercialization expenses, other than royalties and milestones that may be owed by CytRx under its existing license agreements.

In connection with the License Agreement, on July 27, 2017, CytRx (i) entered into a stock purchase agreement with NantCell in which NantCell purchased $13 million of CytRx common stock at $1.10 per share, a 92% premium to market on that date, and (ii) issued to NantCell a warrant to purchase up to 3 million shares of common stock at $1.10, expiring on January 27, 2019.

On July 27, 2017, we entered into a First Amendment to Loan and Security Agreement with Hercules to amend our existing long-term loan facility (the "Loan Agreement") originally entered into on February 5, 2016. The amendment provides for our payment, on July 28, 2017, of $5.0 million in outstanding principal and unpaid interest due under the Loan Agreement, plus a $100,000 prepayment charge, and for our repayment, on or prior to September 30, 2017, of an additional $5.0 million outstanding principal and unpaid interest due under the Loan Agreement, plus an additional prepayment charge. We made the first $5 million payment on July 28, 2017. In connection with the Loan Agreement, in February 2016 we issued the lenders warrants to purchase an aggregate of up to approximately 630,000 shares of our common stock at an exercise price of $2.05 per share. Pursuant to the amendment, a portion of the warrants (representing 80% of the total number of shares issuable upon exercise of the warrants) was amended to change the exercise price of that portion of the warrants from $2.05 per share to a reduced amount, to be calculated based upon the 30-day volume-weighted average price of our common stock over the 30-day period beginning 15 days before the July 28, 2017 announcement of the NantCell license transaction.

Item 2. — Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

All statements in this Quarterly Report, including statements in this section, other than statements of historical fact are forward-looking statements, including statements of our current views with respect to the recent developments regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "could" or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements.

All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2016, which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Overview

On July 27, 2017, CytRx entered into an exclusive worldwide license with NantCell, Inc. ("NantCell"), granting them rights to develop, manufacture and commercialize aldoxorubicin in all indications. As part of the license, NantCell made a strategic investment of $13 million in CytRx common stock at a premium to the market price. CytRx is entitled to receive up to $343 million in milestones related to regulatory approvals and commercial milestones. CytRx is entitled to receive ascending double-digit royalties for net sales for soft tissue sarcomas and mid to high single digit royalties for other indications. NantCell will take over the development and commercialization responsibility for aldoxorubicin including the NDA.

Our current efforts are focused on two classes of ultra-high potency drug conjugates. Our strategy across these programs is to generate additional data that will inform decisions regarding the possible selection for one or both programs for moving into human clinical trials either independently or on a partnered basis.

Critical Accounting Policies and Estimates

Management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, impairment of long-lived assets, including finite-lived intangible assets, research and development expenses and clinical trial expenses and stock-based compensation expense.

We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are summarized in Note 2 to our financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2016. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

Revenue consists of license fees from strategic alliances with pharmaceutical companies, as well as service and grant revenues. Service revenue consists of contract research and laboratory consulting. Grant revenues consist of government and private grants.

Monies received for license fees are deferred and recognized ratably over the performance period in accordance with Financial Accounting Standards Board ("FASB") Accounting Codification Standards ("ASC") ASC 605-25, Revenue Recognition – Multiple-Element Arrangements ("ASC 605-25"). Milestone payments will be recognized upon achievement of the milestone as long as the milestone is deemed substantive and we have no other performance obligations related to the milestone and collectability is reasonably assured, which is generally upon receipt, or recognized upon termination of the agreement and all related obligations. Deferred revenue represents amounts received prior to revenue recognition.

Revenues from contract research, government grants, and consulting fees are recognized over the respective contract periods as the services are performed, provided there is persuasive evidence or an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Once all conditions of the grant are met and no contingencies remain outstanding, the revenue is recognized as grant fee revenue and an earned but unbilled revenue receivable is recorded.

Research and Development Expenses

Research and development expenses consist of direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Costs of technology developed for use in our products are expensed as incurred until technological feasibility has been established.

Clinical Trial Expenses

Clinical trial expenses, which are included in research and development expenses, include obligations resulting from our contracts with various clinical research organizations in connection with conducting clinical trials for our product candidates. We recognize expenses for these activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. We believe that this method best approximates the efforts expended on a clinical trial with the expenses we record. We adjust our rate of clinical expense recognition if actual results differ from our estimates. If our estimates prove incorrect, clinical trial expenses recorded in future periods could vary.

Stock-Based Compensation

Our stock-based employee compensation plans are described in Note 7 of the Notes to Condensed Financial Statements included in this Quarterly Report. We follow ASC 718, Compensation-Stock Compensation ("ASC 718"), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.

For stock options and warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50, Equity-Based Payments to Non-Employees ("ASC 505-50").

Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options is determined using the Black-Scholes option-pricing model, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted or issued to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested.

The fair value of each stock option and warrant is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option-pricing model, based on an expected forfeiture rate that is adjusted for our actual experience. If our Black-Scholes option-pricing model assumptions or our actual or estimated forfeiture rate are different in the future, it could materially affect our compensation expense recorded in future periods. On January 1, 2017, we adopted ASU 2016-09 and made a policy election to recognize forfeitures as they occur. The adoption of ASU 2016-09 did not have a material impact to the Company's financial condition or results of operations. No amounts relating to stock-based compensation have been capitalized.

Impairment of Long-Lived Assets

We review long-lived assets, including finite-lived intangible assets, for impairment on an annual basis as of December 31, or on an interim basis if an event occurs that might reduce the fair value of such assets below their carrying values. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. If our estimates used in the determination of either discounted future cash flows or other appropriate fair value methods are not accurate as compared to actual future results, we may be required to record an impairment charge.

Net Income (Loss) per Share

Basic and diluted net loss per common share is computed using the weighted-average number of common shares outstanding. Potentially dilutive stock options and warrants to purchase 44.8 million shares for each of the three-month and six-month periods ended June 30, 2017, and 22.4 million shares for each of the three-month and six-month periods ended June 30, 2016, were excluded from the computation of diluted net loss per share, because the effect would be anti-dilutive.

Warrant Liabilities

Warrants issued in connection with the Company's July 2016 equity public offering and modified in the Company's December 2016 equity public offering are classified as liabilities as opposed to equity due to their settlement terms. These warrants are non-cash liabilities and the Company is not required to expend any cash to settle these liabilities. In accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company's Own Stock ("ASC 815-40"), the warrant liabilities are marked to market each quarter-end until they are completely settled.The fair value of the warrants is determined using the Black-Scholes option pricing model, which requires the use of significant judgment and estimates for the inputs used in the model. The warrants issued in connection with the Company's August 2011 equity public offering expired in August 2016.

Liquidity and Capital Resources

We have relied primarily upon proceeds from sales of our equity securities and the exercise of options and warrants, and to a much lesser extent upon payments from our strategic partners and licensees, to generate funds needed to finance our business and operation.

At June 30, 2017, we had cash and cash equivalents of approximately $55.0 million. On July 27, 2017, we entered into a global strategic licensing agreement with NantCell Inc ("NantCell") for the exclusive rights to develop, manufacture and commercialize aldoxorbuicin for all indications. Under the terms of this Agreement, NantCell made a strategic investment into our Company by purchasing $13 million of our common stock. Concurrently, we announced the signing of an amendment to the Loan Services Agreement with Hercules whereby we made an immediate principal repayment of $5 million, a further $5 million repayment by September 30, 2017, and an updated schedule of monthly installments with a new Term Loan maturity date of August 1, 2018. Under the NantCell license, NantCell agreed to assume all future costs of developing and commercializing aldoxorubicin. Management believes that our current cash and cash equivalents, along with the net proceeds of the common stock purchase (See Note 13), will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2017 and the first seven months of 2018 of approximately $35.6 million, which includes approximately $4.7 million for our clinical programs for aldoxorubicin, approximately $3.7 million for the research and clinical development of novel anti-cancer drug candidates at our Freiburg operations, approximately $1.1 million for general operation of our clinical programs, approximately $9.4 million for other general and administrative expenses, and approximately $16.6 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

We recorded a net loss in the six-months ended June 30, 2017 of $25.4 million as compared to a net loss in the six-months ended June 30, 2016 of $30.9 million, or a decrease of $5.5 million. This was due primarily to a decrease in our research and development expenditures in the current six-month period of $7.7 million as compared to comparative 2016 period, as our pivotal clinical trial program is winding down; we also realized a decrease of $4.0 million in general and administrative expenditures, offset by an increase in interest on the term loan of $1.0 million and an increase in the loss on warrant deriviative liability of $5.0 million.

We utilized cash of approximately $135,000 for capital expenditures in the six-month period ended June 30, 2017 as compared to approximately $661,000 in the comparable 2016 period. We do not expect any significant capital spending during the next 12 months.

We received a net amount of $14.0 million from the proceeds of a public offering in May, 2017. During the fiscal quarter ended June 30, 2017, we also received net proceeds from the exercise of warrants of approximately $2.8 million, compared to $0.7 million of warrant exercise net proceeds in the comparative 2016 period. We also made principal payments on our Term Loan of $2.4 million; no such payments were made in 2016 since we were granted a twelve month principal payment deferral under the Loan Agreement that we entered into in February 2016.

We continue to evaluate potential future sources of capital, as we do not currently have commitments from any third parties to provide us with additional capital. The results of our technology licensing efforts and the actual proceeds of any fund-raising activities will determine our ongoing ability to operate as a going concern. Our ability to obtain future financings through joint ventures, product licensing arrangements, royalty sales, equity financings, grants or otherwise is subject to market conditions, the ability of our partner to commercialize aldoxorubicin and our ability to identify parties that are willing and able to enter into such arrangements related to our drug development efforts in our German lab on terms that are satisfactory to us. Depending upon the outcome of our fundraising efforts, the accompanying financial information may not necessarily be indicative of our future financial condition.

As a development company that is primarily engaged in research and development activities, we expect to incur significant losses and negative cash flow from operating activities for the foreseeable future. There can be no assurance that we will be able to generate revenues from our product candidates and become profitable. Even if we become profitable, we may not be able to sustain that profitability.

Results of Operations

We recorded a net loss of approximately $14.4 million and $25.4 million for the three-month and six-month periods ended June 30, 2017, respectively, as compared to a net loss of approximately $18.3 million and $30.9 million for the three-month and six-month periods ended June 30, 2016, respectively. The decrease of $3.9 million in our net loss during the current three-month period resulted from a reduction of $6.7 million in the expenditures related to our aldoxorubicin program, a decrease in general and administrative expenses of $3.0 million, due to a reduction in legal fees of $1.0 million and the elimination of our pre-commercial group in the second half of 2016, offset by an increase in the loss on warrant derivative liabilities of $5.2 million and an increase in interest expenses of $0.1 million.

We recognized no licensing revenue in the three and six-month periods ended June 30, 2017 as compared to $0.1 million in the comparative 2016 periods. All future licensing fees under our current licensing agreements are dependent upon successful development milestones being achieved by the licensor. During the remainder of 2017, we do not anticipate receiving any significant licensing fees.

Research and Development

	Three-Month Period Ended June 30,				Six-Month Period Ended June 30,
	2017		2016		2017		2016
	(In thousands)				(In thousands)
Research and development expenses	$	5,719	$	11,845	$	11,967	$	19,425
Employee stock option expense		279		507		632		988
Depreciation and amortization		169		100		335		192
	$	6,167	$	12,452	$	12,934	$	20,605

Research expenses are expenses incurred by us in the discovery of new information that will assist us in the creation and the development of new drugs or treatments. Development expenses are expenses incurred by us in our efforts to commercialize the findings generated through our research efforts. Our research and development expenses, excluding stock option expense, non-cash expenses and depreciation and amortization, were $5.7 million and $12.0 million for the three-month and six-month periods ended June 30, 2017, respectively, and $11.8 million and $19.4 million for the three-month and six-month periods ended June 30, 2016, respectively.

Research and development expenses incurred during the three-month period ended June 30, 2017 related primarily to our aldoxorubicin clinical program. In the three-month and six-month periods ended June 30, 2017, the development expenses of our program for aldoxorubicin were $3.7 million and $7.7 million, respectively, as compared to $10.4 million and $16.2 million for the same periods in 2016, respectively. We incurred $0.9 million and $1.6 million, respectively, for the three-month and six-month periods ended June 30, 2017, for our German lab operations, as compared to $0.5 million and $1.1 million in the 2016 comparative periods. The remainder of our research and development expenses primarily related to research and development support costs. We recorded approximately $0.3 million and $0.6 million of employee stock option expense in the three-month and six-month periods ended June 30, 2017, as compared to $0.5 million and $1.0 million for the same periods in 2016, respectively.

General and Administrative Expenses

	Three-Month Period Ended June 30,				Six-Month Period Ended June 30,
	2017		2016		2017		2016
	(In thousands)				(In thousands)
General and administrative expenses	$	2,609	$	3,586	$	5,002	$	6,689
Non-cash general and administrative expenses		36		33		65		220
Employee stock option expense		485		2,499		1,035		3,156
Depreciation and amortization		7		11		14		22
	$	3,137	$	6,129	$	6,116	$	10,087

General and administrative expenses include all administrative salaries and general corporate expenses, including legal expenses. Our general and administrative expenses, excluding stock option expense, non-cash expenses and depreciation and amortization, were $2.6 million and $5.0 million for the three and six-month periods ended June 30, 2017, respectively, and $3.6 million and $6.7 million, respectively, for the same periods in 2016.

Employee stock option expense relates to options granted to retain and compensate directors, officers and other employees. We recorded, in total, approximately $0.5 million and $1.0 million of employee stock option expense in the three-month and six-month periods ended June 30, 2017, respectively, as compared to $2.5 million and $3.2 million, respectively, for the same periods in 2016. In the three-month period ended June 30, 2016, we amended the terms of stock options of a former executive in respect of a Retirement Agreement, resulting in a one-time expense of approximately $1.9 million. We recorded approximately $36,000 and $65,000 of non-employee stock option expense in the three-month and six-month periods, ended June 30, 2017, respectively, and $33,000 and $0.2 million for the comparative 2016 periods.

Depreciation and Amortization

Depreciation expense reflects the depreciation of our equipment and furnishings.

Interest Income and Expense

Interest income was approximately $91,000 and $151,000 for the three-month and six-month periods ended June 30, 2017, respectively, as compared to $65,000 and $127,000, respectively, for the same periods in 2016. This increase was related to the increase in cash and cash equivalents and short term investments.

Interest expense was approximately $0.9 million and $2.2 million for the three-month and six-month periods ended June 30, 2017, respectively as compared to $0.7 million and $1.2 million for the comparative 2016 periods.

Item 3. — Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any speculative or hedging derivative financial instruments or foreign currency instruments. If interest rates had varied by 10% in the three-month period ended June 30, 2017, it would not have had a material effect on our results of operations or cash flows for that period.

Item 4. — Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of the end of the quarterly period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.

Changes in Controls over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2017 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We continually seek to assure that all of our controls and procedures are adequate and effective. Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to meet our reporting obligations under the SEC's rules and regulations. Any failure to improve our internal controls to address the weakness we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our common stock.

PART II — OTHER INFORMATION

Item 1. — Legal Proceedings

The disclosure set forth in Note 12 to our financial statements is herein incorporated by reference.

Item 6. — Exhibits

The exhibits listed in the accompanying Index to Exhibits are filed as part of this Quarterly Report and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CYTRX CORPORATION

August 3, 2017	By:	/s/ JOHN Y. CALOZ
		Name: John Y. Caloz
		Title: Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number		Description
31.1		Certification of Chief Executive Officer Pursuant to 17 CFR 240.13a-14(a)
31.2		Certification of Chief Financial Officer Pursuant to 17 CFR 240.13a-14(a)
32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Schema Document
101.CAL		XBRL Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Label Linkbase Document
101.PRE		XBRL Presentation Linkbase Document

______________________________

EX-31.1 2 exh31-1.htm

Exhibit 31.1

CERTIFICATIONS

I, Steven A. Kriegsman, Chief Executive Officer of CytRx Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytRx Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

	CYTRX CORPORATION

August 3, 2017	By:	/s/ STEVEN A. KRIEGSMAN
		Name: Steven A. Kriegsman
		Title: Chief Executive Officer

EX-31.2 3 exh31-2.htm

Exhibit 31.2

CERTIFICATIONS

I, John Y. Caloz, Chief Financial Officer of CytRx Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytRx Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

	CYTRX CORPORATION

August 3, 2017	By:	/s/ JOHN Y. CALOZ
		Name: John Y. Caloz
		Title: Chief Financial Officer

EX-32.1 4 exh32-1.htm

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CytRx Corporation (the "Company") hereby certifies based on his knowledge that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in the Report.

	CYTRX CORPORATION

August 3, 2017	By:	/s/ STEVEN A KRIEGSMAN
		Name: Steven A. Kriegsman
		Title: Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (Section 906), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CytRx Corporation and will be retained by CytRx Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.

EX-32.2 5 exh32-2.htm

Exhibit 32.2

Certification of Chief Financial Officer

	CYTRX CORPORATION

August 3, 2017	By:	/s/ JOHN Y. CALOZ
		Name: John Y. Caloz
		Title: Chief Financial Officer

The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.

EX-101.INS 6 cytr-20170630.xml XBRL INSTANCE DOCUMENT 0000799698 2017-01-01 2017-06-30 0000799698 2017-08-03 0000799698 2017-06-30 0000799698 2016-12-31 0000799698 us-gaap:SeriesAPreferredStockMember 2017-06-30 0000799698 us-gaap:SeriesBPreferredStockMember 2017-06-30 0000799698 us-gaap:SeriesBPreferredStockMember 2016-12-31 0000799698 us-gaap:SeriesAPreferredStockMember 2016-12-31 0000799698 2017-04-01 2017-06-30 0000799698 2016-04-01 2016-06-30 0000799698 2016-01-01 2016-06-30 0000799698 2015-12-31 0000799698 2016-06-30 0000799698 us-gaap:SubsequentEventMember cytr:NantCellIncMember 2017-07-27 2017-07-27 0000799698 us-gaap:SubsequentEventMember cytr:NantCellIncMember 2017-07-27 0000799698 us-gaap:SubsequentEventMember cytr:NantCellIncMember us-gaap:MaximumMember 2017-07-27 2017-07-27 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-02-08 2016-02-08 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:PrimeRateMember 2016-02-05 2016-02-05 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-02-05 2016-02-05 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-02-05 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:WarrantMember 2016-02-05 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:WarrantMember 2017-06-30 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2017-01-01 2017-06-30 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-12-31 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2017-06-30 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:ScenarioForecastMember 2017-07-29 2017-09-30 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:SubsequentEventMember 2017-07-28 2017-07-28 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2017-04-01 2017-06-30 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-04-01 2016-06-30 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-01-01 2016-06-30 0000799698 us-gaap:WarrantMember 2016-04-01 2016-06-30 0000799698 us-gaap:WarrantMember 2017-04-01 2017-06-30 0000799698 us-gaap:WarrantMember 2016-01-01 2016-06-30 0000799698 us-gaap:WarrantMember 2017-01-01 2017-06-30 0000799698 us-gaap:WarrantMember 2017-06-30 0000799698 us-gaap:WarrantMember 2016-06-30 0000799698 us-gaap:SubsequentEventMember 2017-07-19 2017-07-19 0000799698 cytr:LongTermIncentivePlanMember 2017-01-01 2017-06-30 0000799698 cytr:StockIncentivePlanMember 2017-06-30 0000799698 cytr:LongTermIncentivePlanMember 2017-06-30 0000799698 cytr:StockIncentivePlanMember us-gaap:RestrictedStockMember 2017-06-30 0000799698 us-gaap:WarrantMember 2016-06-30 0000799698 cytr:FormerExecutiveMember us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0000799698 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000799698 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000799698 us-gaap:MaximumMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000799698 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0000799698 cytr:NonEmployeesMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000799698 us-gaap:EmployeeStockOptionMember cytr:EmployeesMember 2016-01-01 2016-06-30 0000799698 us-gaap:DirectorMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000799698 us-gaap:ManagementMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000799698 cytr:EmployeesAndDirectorsMember 2017-06-30 0000799698 cytr:EmployeesAndDirectorsMember 2017-01-01 2017-06-30 0000799698 us-gaap:EmployeeStockOptionMember 2016-12-31 0000799698 cytr:EmployeesMember us-gaap:EmployeeStockOptionMember 2016-12-31 0000799698 us-gaap:EmployeeStockOptionMember cytr:NonEmployeesMember 2016-12-31 0000799698 cytr:NonEmployeesMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000799698 cytr:EmployeesMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000799698 us-gaap:EmployeeStockOptionMember cytr:NonEmployeesMember 2017-06-30 0000799698 us-gaap:EmployeeStockOptionMember 2017-06-30 0000799698 cytr:EmployeesMember us-gaap:EmployeeStockOptionMember 2017-06-30 0000799698 us-gaap:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember cytr:StockIncentivePlanMember 2016-01-01 2016-12-31 0000799698 us-gaap:RestrictedStockMember 2016-04-01 2016-06-30 0000799698 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0000799698 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000799698 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0000799698 cytr:EmployeesMember cytr:StockOptionsAndWarrantsMember 2017-04-01 2017-06-30 0000799698 cytr:StockOptionsAndWarrantsMember us-gaap:GeneralAndAdministrativeExpenseMember cytr:EmployeesMember 2017-01-01 2017-06-30 0000799698 cytr:StockOptionsAndWarrantsMember cytr:EmployeesMember 2016-04-01 2016-06-30 0000799698 cytr:StockOptionsAndWarrantsMember us-gaap:ResearchAndDevelopmentExpenseMember cytr:NonEmployeesMember 2016-04-01 2016-06-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember cytr:EmployeesMember cytr:StockOptionsAndWarrantsMember 2016-04-01 2016-06-30 0000799698 cytr:StockOptionsAndWarrantsMember cytr:EmployeesMember 2016-01-01 2016-06-30 0000799698 cytr:StockOptionsAndWarrantsMember us-gaap:GeneralAndAdministrativeExpenseMember cytr:EmployeesMember 2016-01-01 2016-06-30 0000799698 cytr:NonEmployeesMember cytr:StockOptionsAndWarrantsMember 2016-01-01 2016-06-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember cytr:StockOptionsAndWarrantsMember cytr:NonEmployeesMember 2016-01-01 2016-06-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember cytr:StockOptionsAndWarrantsMember cytr:NonEmployeesMember 2016-01-01 2016-06-30 0000799698 cytr:EmployeesMember us-gaap:GeneralAndAdministrativeExpenseMember cytr:StockOptionsAndWarrantsMember 2017-04-01 2017-06-30 0000799698 cytr:StockOptionsAndWarrantsMember us-gaap:GeneralAndAdministrativeExpenseMember cytr:NonEmployeesMember 2017-04-01 2017-06-30 0000799698 cytr:StockOptionsAndWarrantsMember cytr:EmployeesMember 2017-01-01 2017-06-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember cytr:StockOptionsAndWarrantsMember cytr:EmployeesMember 2016-01-01 2016-06-30 0000799698 cytr:NonEmployeesMember cytr:StockOptionsAndWarrantsMember 2017-01-01 2017-06-30 0000799698 cytr:StockOptionsAndWarrantsMember us-gaap:GeneralAndAdministrativeExpenseMember cytr:NonEmployeesMember 2017-01-01 2017-06-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember cytr:StockOptionsAndWarrantsMember cytr:NonEmployeesMember 2016-04-01 2016-06-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember cytr:EmployeesMember cytr:StockOptionsAndWarrantsMember 2017-04-01 2017-06-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember cytr:StockOptionsAndWarrantsMember cytr:EmployeesMember 2017-01-01 2017-06-30 0000799698 cytr:StockOptionsAndWarrantsMember cytr:NonEmployeesMember 2017-04-01 2017-06-30 0000799698 cytr:NonEmployeesMember cytr:StockOptionsAndWarrantsMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0000799698 cytr:EmployeesMember us-gaap:GeneralAndAdministrativeExpenseMember cytr:StockOptionsAndWarrantsMember 2016-04-01 2016-06-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember cytr:StockOptionsAndWarrantsMember cytr:NonEmployeesMember 2017-01-01 2017-06-30 0000799698 cytr:NonEmployeesMember cytr:StockOptionsAndWarrantsMember 2016-04-01 2016-06-30 0000799698 us-gaap:EmployeeStockOptionMember cytr:RangeFourMember 2017-01-01 2017-06-30 0000799698 cytr:RangeOneMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000799698 cytr:RangeThreeMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000799698 cytr:RangeTwoMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000799698 cytr:RangeOneMember us-gaap:EmployeeStockOptionMember 2017-06-30 0000799698 us-gaap:EmployeeStockOptionMember cytr:RangeFourMember 2017-06-30 0000799698 us-gaap:EmployeeStockOptionMember cytr:RangeTwoMember 2017-06-30 0000799698 us-gaap:EmployeeStockOptionMember cytr:RangeThreeMember 2017-06-30 0000799698 us-gaap:WarrantMember 2017-06-30 0000799698 us-gaap:WarrantMember 2016-12-31 0000799698 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000799698 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000799698 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0000799698 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000799698 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0000799698 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000799698 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0000799698 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000799698 cytr:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:SubsequentEventMember 2017-07-27 2017-07-27 0000799698 cytr:OtherGeneralAndAdministrativeExpensesMember 2017-01-01 2017-06-30 0000799698 cytr:AldoxorubicinMember 2017-01-01 2017-06-30 0000799698 cytr:InterestAndTermLoanPaymentMember 2017-01-01 2017-06-30 0000799698 cytr:OtherProgramsMember 2017-01-01 2017-06-30 0000799698 cytr:GeneralOperationMember 2017-01-01 2017-06-30 0000799698 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0000799698 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-03-31 0000799698 2017-05-02 2017-05-02 0000799698 us-gaap:DomesticCountryMember 2016-12-31 0000799698 us-gaap:DomesticCountryMember cytr:UnrestrictedMember 2016-12-31 0000799698 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0000799698 cytr:UnrestrictedMember us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0000799698 us-gaap:EarliestTaxYearMember 2017-01-01 2017-06-30 0000799698 us-gaap:LatestTaxYearMember 2017-01-01 2017-06-30 0000799698 cytr:NantCellIncMember 2017-01-01 2017-06-30 0000799698 cytr:NantCellIncMember 2017-06-30 0000799698 us-gaap:MaximumMember us-gaap:SubsequentEventMember cytr:NantCellIncMember 2017-07-27 xbrli:shares iso4217:USD iso4217:USD xbrli:shares cytr:Patient xbrli:pure cytr:Class cytr:Complaint false --12-31 2017-06-30 No No Yes Accelerated Filer CYTRX CORP 0000799698 165710526 2017 Q2 10-Q

3830498

2972082

6406445

7080080

460329472

437423958

83029

165146

680353

869485

3006563

507195

4144424

3156418

220462

401820

36578

1501101

988006

65237

32506

278533

631616

36578

2499368

32506

1900000

208148

975743

22400000

44800000

22400000

58347991

62769784

56802618

60577426

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-weight: bold;">1.</font>  <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Description of Company and Basis of Presentation</font></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">CytRx Corporation ("we," "us," "our," CytRx" or the "company") is a biopharmaceutical company specializing in oncology.  Our focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor.  Aldoxorubicin, our lead clinical candidate, has been tested in over 600 patients with various types of cancer.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">CytRx's lead product candidate is aldoxorubicin, a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor.  Specifically, it is comprised of (6-maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin.  Our lead indication for aldoxorubicin is for patients with advanced soft tissue sarcomas (STS). We met with the FDA in March 2017 to discuss a regulatory pathway for a New Drug Application (NDA) for aldoxorubicin in STS.</div><div style="text-align: left; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">Aldoxorubicin has received Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of STS. ODD provides several benefits including seven years of market exclusivity after approval, certain R&D related tax credits, and protocol assistance by the FDA. European regulators granted aldoxorubicin Orphan designation for STS which confers ten years of market exclusivity among other benefits.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">On July 27, 2017, CytRx entered into an exclusive worldwide license with NantCell, Inc. ("NantCell"), granting them rights to develop, manufacture and commercialize aldoxorubicin in all indications.  As part of the license, NantCell made a strategic investment of $13 million in CytRx common stock $1.10 per share, a premium of 92% to the market price on that date.  CytRx is entitled to receive up to $343 million in milestones related to regulatory approvals and commercial milestones.  CytRx is entitled to receive ascending double-digit royalties for net sales for soft tissue sarcomas and mid to high single digit royalties for other indications.  NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin including the cost of filing the NDA.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">CytRx has an active drug discovery and research operation at our laboratory facilities in Freiburg, Germany, focusing on the creation of novel drug anti-cancer candidates by combining our proprietary linker technologies with ultra-high potency cytotoxic drugs. We are expanding our pipeline of ultra-high potency oncology candidates through our LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and next generation linker technologies for the development of a new class of potential breakthrough anti-cancer therapies.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">We have created a "toolbox" of linker technologies that have the ability to significantly increase the therapeutic index of ultra-high potency drugs (10-1,000 times more potent than traditional chemotherapies) by controlling the release of the drug payloads and improving drug-like properties. After infusion, these ultra-high potency drug conjugates bind to circulating albumin for transport of the drug to the tumor.  Subsequently, due to specific conditions within the tumor, the linkers are cleaved and release the anti-cancer drug payload.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">Our current efforts are focused on two classes of ultra-high potency drug conjugates.  Our strategy across these programs is to generate additional pre-clinical data that will allow us to make informed decisions regarding the selection of one or both programs for moving into human clinical trials either independently or on a partnered basis.</div><div><br /></div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The accompanying condensed financial statements at June 30, 2017 and for the three-month and six-month periods ended June 30, 2017 and 2016, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2016 have been derived from the our audited financial statements as of that date.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company's audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2016.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">As a result of the worldwide license of all of our rights to aldoxorubicin to NantCell, NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin, thereby enabling us to eliminate our future research and development activities related to aldoxorubicin. Currently, our only research and development activities are conducted by our Freiburg, Germany, laboratory facility.  For this reason and others, our operating expenses are expected to be significantly lower in the near future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.</div></div>

79247

54972846

56959485

22261372

55913199

33651827

-1986639

53485000

56276000

53485000

56276000

634146

500000

630000

3000000

24110577

6371854

2.05

1.74

2.05

1.10

153127389

111322895

250000000

111321

153126

10400000

0.001

111322895

153127389

600000

7400

18581244

9304082

30691899

19050121

0.0600

0.1025

2020-02-01

2018-08-01

213964

348843

6567080

3789391

877729

-4336066

-4303945

693457

877729

-4303945

693457

-4336066

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-bottom: 12pt; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">7</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</font><font style="font-size: 1px; display: inline-block; width: 36pt;"> </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Stock Based Compensation</font></div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">We have a 2000 Long-Term Incentive Plan, which expired on August 6, 2010.  As of June 30, 2017, there were approximately 0.4 million shares subject to outstanding stock options under this plan.  No further shares are available for future grant under this plan.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">We also have a 2008 Stock Incentive Plan.  As of June 30, 2017, there were 16.4 million shares subject to outstanding stock options and 2.5 million shares outstanding related to restricted stock grants options and 10.4 million shares available for future grant under this plan.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">We follow ASC 718, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Compensation-Stock Compensation, </font>which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. As a result, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Statements of Operations:</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three Months Ended June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Research and development — employee</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">278,533</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">507,195</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">631,616</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">988,006</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">General and administrative — employee</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">401,820</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,499,368</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">869,485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,156,418</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 24.45pt; margin-right: 5.05pt; text-indent: -5.05pt;">Total employee stock-based compensation</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">680,353</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,006,563</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,501,101</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,144,424</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Research and development — non-employee</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">General and administrative — non-employee</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">36,578</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">32,506</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">65,237</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">220,462</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 24.45pt; margin-right: 5.05pt; text-indent: -5.05pt;">Total non-employee stock-based compensation</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">36,578</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">32,506</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">65,237</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">220,462</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div><br /></div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">During the six-month period ended June 30, 2017, we granted stock options to purchase 10,000 shares of our common stock at an average weighted exercise price of $0.41. During the six-month period ended June 30, 2016, we granted stock options to purchase 425,000 shares of our common stock and warrants to purchase 500,000 shares of our common stock at a weighted average exercise price of $1.74. In the three-month period ended June 30, 2016, we amended the terms of stock options of a former executive in respect of a Retirement Agreement, resulting in a one-time expense of approximately $1.9 million. </div><div style="page-break-after: always; text-indent: 36pt;">The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:</div><div style="page-break-after: always;"> </div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">June 30, 2017</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">June 30, 2016</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Risk-free interest rate</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1.47</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Expected volatility</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">85.5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">76.3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Expected lives (years)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5 - 10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Expected dividend yield</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;"> </div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">Our computation of expected volatility is based on the historical daily volatility of our publicly traded stock.  We use historical information to compute expected lives. In the six-month period ended June 30, 2017, the contractual term of the options granted was ten years. The dividend yield assumption of zero is based upon the fact we have never paid cash dividends and presently have no intention to do so.  The risk-free interest rate used for each grant and issuance is equal to the U.S. Treasury rates in effect at the time of the grant and issuance for instruments with a similar expected life. Based on historical experience, for the six-month period ended June 30, 2016, we estimated annualized forfeiture rates of 10% for options granted to our employees, 2% for options granted to senior management and 0% for options granted to directors and non-employees and for warrants issued to non-employees  Compensation costs will be adjusted for future changes in estimated forfeitures.  We will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. On January 1, 2017, we adopted ASU 2016-09 and made a policy election to recognize forfeitures as they occur. The adoption of ASU 2016-09 did not have a material impact to the Company's financial condition or results of operations. No amounts relating to stock-based compensation have been capitalized.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">As of June 30, 2017, there remained approximately $2.4 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors, to be recognized as expense over a weighted-average period of 1.01 years. Presented below is our stock option activity:</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="14" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended June 30, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Number of Options <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(Employees)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Number of Options <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(Non-Employees)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Total Number of<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Options</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Outstanding at January 1, 2017</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,879,770</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">17,479,770</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.37</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 14.75pt; margin-right: 5.05pt; text-indent: -5.05pt;">Granted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 14.75pt; margin-right: 5.05pt; text-indent: -5.05pt;">Exercised, Forfeited or Expired</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(646,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(</font>646,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Outstanding at June 30, 2017</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,242,923</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,842,932</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Options exercisable at June 30, 2017</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11,655,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12,255,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.75</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2017:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Range of Exercise<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Prices</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Total Number <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">of Options</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average Remaining Contractual Life<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (years)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Total Number of Options <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercisable</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average Remaining Contractual Life<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (years)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.41 - $1.50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,317,533</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9.45</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,586,461</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9.46</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1.51 – $2.50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,669,296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.32</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.26</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,835,946</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.07</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.22</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.51 – $4.00</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">960,670</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6.64</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.88</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">937,337</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6.61</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.87</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4.01 – $32.55</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,895,424</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.69</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.24</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,895,424</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.69</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.24</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,842,923</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.55</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12,255,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.02</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.75</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div><br /></div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The aggregate intrinsic value of all outstanding options and vested options as of June 30, 2017 was $0.8 million and $0.3 million, respectively, representing options with exercise prices of less than the closing fair market value of our common stock on June 30, 2017 of $0.63 per share.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">There were 27,989,723 and 32,502,790 warrants outstanding at June 30, 2017 and December 31, 2016, respectively both at a weighted-average exercise price of $0.68.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; text-indent: 14.4pt;">Restricted Stock</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">In December 2016, the Company granted to our Chairman and Chief Executive Officer, 2,325,581 shares of restricted common stock, pursuant to the 2008 Plan. This restricted stock vests in equal annual instalments over three years.  The fair value of the restricted stock is based on the market price of the Company's shares on the grant date less the par value received as consideration. The fair value of the restricted stock on the grant date was $1,000,000. The Company recorded an employee stock-based compensation expense for restricted stock of approximately $83,029 and $165,146 respectively, for the three and six-month periods ended June 30, 2017 as compared to zero for the comparative 2016 periods.</div></div>

-0.10

-0.27

-0.46

-0.20

P1Y0M4D

2400000

2800000

-3388

-421843

3137008

6128904

6116063

10087340

183780

800

673635

-844373

-4368773

-136072

-28130

-4297864

-1026781

-1662994

-1432127

741346

848395

2171110

1158148

848395

741346

2171110

1158148

1212219

752083

90849

65436

151392

127174

37992500

39133789

62769784

58347991

23320282

19507990

100000

-700000

5481656

6701040

5481656

18484510

15813507

18484510

15813507

700000

-16142502

-25439613

-134598

34374662

-18280223

-14358297

-25402401

-30923335

14290461

24716778

339000000

152000000

224000000

145000000

-9304082

-18481244

-30591899

-19050121

2017-12-31

2036-12-31

6200

600

1300

5800

38014

48911

7276

-798

3504

6081

-35035420

134598

660758

6000000

5000000

3900

5000000

3900

25000

0.01

3108

3108000

1782141

3434238

704700

2766605

13951218

24012078

25000000

13000000

1959667

1323579

47631

183703

2427362

5000000

12452340

6167074

20604559

12934058

-415865995

-441268396

P9Y5M12D

P7Y3M25D

P7Y6M18D

P6Y7M20D

P5Y8M8D

P6Y7M10D

P5Y8M8D

P7Y0M7D

P7Y0M25D

P9Y5M16D

5.24

2.75

2.87

0.44

2.22

P10Y

P0Y9M14D

P0Y1M2D

P6Y

P10Y

P5Y

2.26

0.44

2.34

2.88

5.24

1.10

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>Presented below is our stock option activity:</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="14" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended June 30, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Number of Options <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(Employees)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Number of Options <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(Non-Employees)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Total Number of<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Options</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Outstanding at January 1, 2017</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,879,770</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">17,479,770</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.37</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 14.75pt; margin-right: 5.05pt; text-indent: -5.05pt;">Granted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.41</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 14.75pt; margin-right: 5.05pt; text-indent: -5.05pt;">Exercised, Forfeited or Expired</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(646,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(</font>646,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Outstanding at June 30, 2017</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,242,923</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,842,932</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 5.05pt; margin-right: 5.05pt; text-indent: -5.05pt;">Options exercisable at June 30, 2017</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11,655,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">600,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12,255,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.75</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="page-break-after: always; text-indent: 36pt;">The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:</div><div style="page-break-after: always;"> </div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">June 30, 2017</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six Months Ended <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">June 30, 2016</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Risk-free interest rate</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1.47</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Expected volatility</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">85.5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">76.3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Expected lives (years)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5 - 10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Expected dividend yield</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">following</font> table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">(In thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Level I</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Level II</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Level III</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">53,485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">53,485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Warrant liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(6,567</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(6,567</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr></table><div><br /></div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The following table summarizes fair value measurements by level at December 31, 2016 for assets and liabilities measured at fair value on a recurring basis:</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">(In thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Level I</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Level II</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Level III</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">56,276</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">56,276</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Warrant liabilities</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">—</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,789</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,789</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>The loan and security agreement contains customary representations, warranties and covenants.</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">June 30, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">December 31, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Term Loan Principal – Current</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,737,492</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,214,057</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Issuance Cost/Loan Discount – Current</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,036,452</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(732,401</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Term Loan, Net – Current</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,701,040</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,481,656</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Long Term Loan Principal</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">14,835,146</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18,785,943</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">End Fee Payable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,771,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,771,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Long Term Loan Discount/Issuance Cost</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(792,889</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(2,072,683</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 76%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Long Term Loan, Net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,813,507</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18,484,510</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2017:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Range of Exercise<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Prices</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Total Number <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">of Options</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average Remaining Contractual Life<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (years)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Total Number of Options <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercisable</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average Remaining Contractual Life<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (years)</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Weighted-Average <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.41 - $1.50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,317,533</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9.45</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,586,461</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9.46</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.44</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1.51 – $2.50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,669,296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.32</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.26</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,835,946</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.07</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.22</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.51 – $4.00</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">960,670</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6.64</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.88</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">937,337</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6.61</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.87</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4.01 – $32.55</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,895,424</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.69</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.24</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,895,424</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.69</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.24</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,842,923</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.55</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.34</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12,255,168</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.02</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.75</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>

4364886

1731484

0.41

6340148

P3Y

27989723

32502790

0.63

2010-08-06

2325581

2500000

2.75

0.0113

0.0020

0.0147

0.0204

11655168

600000

12255168

0.0000

1000000

10400000

0.593

1.253

0.855

0.763

2.37

2.34

300000

16400000

400000

17479770

16879770

600000

16842932

16242923

425000

10000

800000

4317533

2895424

8669296

960670

16842923

6835946

12255168

1586461

937337

2895424

4.00

1.50

2.50

32.55

4.01

0.41

2.51

1.51

30000000

7400000

3108

24777284

19214202

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">13. Subsequent Events</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">On July 27, 2017, we entered into a global strategic license agreement (the "License Agreement") with NantCell, Inc. ("NantCell"), for providing NantCell the exclusive rights to develop and commercialize aldoxorubicin for all indications. Under the terms of the License Agreement, CytRx is entitled to receive up to $343 million in milestone payments related to regulatory approvals and commercial milestones for aldoxorubicin. In addition, CytRx will receive certain specified royalties for all other indications (our receipt of which would obligate us to make certain payments to KTB). NantCell will be responsible for all future development, manufacturing and commercialization expenses, other than royalties and milestones that may be owed by CytRx under its existing license agreements.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">In connection with the License Agreement, on July 27, 2017, CytRx (i) entered into a stock purchase agreement with NantCell in which NantCell purchased $13 million of CytRx common stock at $1.10 per share, a 92% premium to market on that date, and (ii) issued to NantCell a warrant to purchase up to 3 million shares of common stock at $1.10, expiring on January 27, 2019.</div><div style="margin-bottom: 12pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">On July 27, 2017, we entered into a First Amendment to Loan and Security Agreement with Hercules  to amend our existing long-term loan facility (the "Loan Agreement") originally entered into on February 5, 2016. The amendment provides for our payment, on July 28, 2017, of $5.0 million in outstanding principal and unpaid interest due under the Loan Agreement, plus a $100,000 prepayment charge, and for our repayment, on or prior to September 30, 2017, of an additional $5.0 million outstanding principal and unpaid interest due under the Loan Agreement, plus an additional prepayment charge. We made the first $5 million payment  on July 28, 2017.  In connection with the Loan Agreement, in February 2016 we issued the lenders warrants to purchase an aggregate of up to approximately 630,000 shares of our common stock at an exercise price of $2.05 per share. Pursuant to the amendment, a portion of the warrants (representing 80% of the total number of shares issuable upon exercise of the warrants) was amended to change the exercise price of that portion of the warrants from $2.05 per share to a reduced amount, to be calculated based upon the 30-day volume-weighted average price of our common stock over the 30-day period beginning 15 days before the July 28, 2017 announcement of the NantCell license transaction.</div></div>

139070329

67398837

126394244

66893846

EX-101.SCH 7 cytr-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Description of Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Foreign Currency Remeasurement link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Term Loan link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Basic and Diluted Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Warrant Liabilities link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Warrant Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Description of Company and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Foreign Currency Remeasurement (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Warrant Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 090702 - Disclosure - Stock Based Compensation, Schedule of Employee and Non Employee Service Share Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 090704 - Disclosure - Stock Based Compensation, by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cytr-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cytr-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cytr-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Domain] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Legal Entity [Axis] Document Type Award Type [Axis] Accrued expenses and other current liabilities Accounts Payable and Other Accrued Liabilities, Current Accounts payable Accounts Payable, Current Additional paid-in capital Adjustments to reconcile net loss to net cash used in operating activities: Restricted stock expense Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition Allocated employee and non-employee stock-based compensation expense, Total Allocated Share-based Compensation Expense, Net of Tax Share based compensation expense Amortization of loan cost and discount Antidilutive securities excluded from computation of earnings per share (in shares) Total assets Assets ASSETS Assets [Abstract] Current assets: Total current assets Assets, Current Description of Company and Basis of Presentation Business Description and Basis of Presentation [Text Block] Equipment and furnishings purchased on credit Cash and cash equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash equivalents Chairman and Chief Executive Officer [Member] Number of warrants issued (in shares) Warrants to purchase shares of common stock (in shares) Class of Stock [Line Items] Warrants classified as liabilities (in shares) Class of Stock [Domain] Exercise price of warrants (in dollars per share) Warrants exercise price (in dollars per share) Warrants exercise price (in dollars per share) Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Commitments and contingencies [Abstract] Common Stock [Member] Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, $0.001 par value, 250,000,000 shares authorized; 153,127,389 shares issued and outstanding at June 30, 2017; 111,322,895 shares issued and outstanding at December 31, 2016 Common Stock, Value, Issued Authorized but unissued shares of common stock (in shares) Common Stock, Capital Shares Reserved for Future Issuance Common stock, par value (in dollars per share) Common stock, shares outstanding (in shares) Obligation payable Contractual Obligation Preferred stock conversion Total expenses Costs and Expenses Debt Instrument [Line Items] Term Loan Term Loan [Abstract] Schedule of Long-term Debt Instruments [Table] Debt instrument, basis spread on variable rate Debt instrument, interest rate Maturity date of amended loan servicing agreement Debt instrument, maturity date Depreciation and amortization Depreciation, Depletion and Amortization Derivative Instrument [Axis] Derivative [Line Items] Derivative [Table] Warrant liabilities Derivative Liability, Current Gain (loss) on warrant derivative liabilities Fair value adjustment on warrant liabilities Gain (loss) on warrant derivative liabilities Derivative Contract [Domain] Directors [Member] Stock Based Compensation Stock Based Compensation [Abstract] Federal [Member] Earliest Tax Year [Member] Basic and diluted net loss per share (in dollars per share) Basic and Diluted Net Loss Per Common Share Earnings Per Share [Text Block] Basic and Diluted Net Loss Per Common Share [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Unrecognized compensation cost, recognized as expense over a weighted-average period Stock Options [Member] Unrecognized compensation expense related to unvested stock options, granted Investment, Name [Domain] Equity Component [Domain] Increase in fair value of warrant liabilities Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Fair Value Measurements [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Measurement Frequency [Domain] Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Hierarchy [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Fair value measurements by level for assets and liabilities measured at fair value on a recurring basis [Abstract] Level III [Member] Level I [Member] Level II [Member] Foreign Currency Remeasurement Foreign Currency Remeasurement [Abstract] Loss on retirement of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property General and administrative General and Administrative Expense [Member] Goodwill Income Taxes [Abstract] Income Statement Location [Axis] Income Statement Location [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Taxes Income Tax Disclosure [Text Block] CONDENSED STATEMENTS OF OPERATIONS (Unaudited) [Abstract] Cash paid for income taxes Accounts payable Receivables Increase (Decrease) in Accounts Receivable Interest receivable Increase (Decrease) in Accrued Interest Receivable, Net Accrued expenses and other current liabilities Changes in assets and liabilities: Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Interest expense Interest expense Interest Expense Cash paid during the year for interest Interest income Latest Tax Year [Member] Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Total current liabilities Liabilities, Current Current liabilities: License revenue Licenses Revenue Non-cash litigation settlement due in common stock Litigation Settlement, Amount Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale, Name [Domain] Term loan, net - current Term Loan, Net - Current Long term loan, net Long Term Loan, Net Loss Contingencies [Table] Litigation settlement Loss Contingencies [Line Items] Senior Management [Member] Management [Member] Maximum [Member] Minimum [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from financing activities: Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Cash flows from operating activities: Net loss Net loss Net Income (Loss) Attributable to Parent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements [Abstract] Supplemental disclosure of non-cash activities: Noncash Investing and Financing Items [Abstract] Other income (loss): Expenses: Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Operating loss carryforwards Operating Loss Carryforwards Loss before other income (loss) Operating Income (Loss) Expiration date Operating Loss Carryforwards, Expiration Date Gain on foreign currency translation adjustment Other assets Other income (loss), net Prime Rate [Member] Proceeds from the sale of short-term investments Payments for (Proceeds from) Short-term Investments Purchases of equipment and furnishings Payments to Acquire Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Amount of milestone payment payable Preferred Stock, shares issued (in shares) Preferred Stock, shares authorized (in shares) Preferred Stock, par value (in dollars per share) EX-101.PRE 11 cytr-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 03, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CYTRX CORP
Entity Central Index Key	0000799698
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		165,710,526
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 54,972,846	$ 56,959,485
Receivables	47,631	183,703
Prepaid expenses and other current assets	1,782,141	3,434,238
Total current assets	56,802,618	60,577,426
Equipment and furnishings, net	1,323,579	1,959,667
Goodwill	183,780	183,780
Other assets	38,014	48,911
Total assets	58,347,991	62,769,784
Current liabilities:
Accounts payable	7,080,080	6,406,445
Accrued expenses and other current liabilities	2,972,082	3,830,498
Warrant liabilities	6,567,080	3,789,391
Term loan, net - current	6,701,040	5,481,656
Total current liabilities	23,320,282	19,507,990
Long term loan, net	15,813,507	18,484,510
Total liabilities	39,133,789	37,992,500
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value, 250,000,000 shares authorized; 153,127,389 shares issued and outstanding at June 30, 2017; 111,322,895 shares issued and outstanding at December 31, 2016	153,126	111,321
Additional paid-in capital	460,329,472	437,423,958
Accumulated deficit	(441,268,396)	(415,865,995)
Total stockholders' equity	19,214,202	24,777,284
Total liabilities and stockholders' equity	58,347,991	62,769,784
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity:
Preferred Stock	0	0
Series B Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred Stock	$ 0	$ 3,108,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Stockholders' equity:
Preferred Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred Stock, shares issued (in shares)	0	0
Preferred Stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	153,127,389	111,322,895
Common stock, shares outstanding (in shares)	153,127,389	111,322,895
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, shares authorized (in shares)	25,000	25,000
Series B Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred Stock, stated value	$ 1,000	$ 1,000
Preferred Stock, shares authorized (in shares)	3,900	3,900
Preferred Stock, shares outstanding (in shares)	0	3,108

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
License revenue	$ 0	$ 100,000	$ 0	$ 100,000
Expenses:
Research and development	6,167,074	12,452,340	12,934,058	20,604,559
General and administrative	3,137,008	6,128,904	6,116,063	10,087,340
Total expenses	9,304,082	18,581,244	19,050,121	30,691,899
Loss before other income (loss)	(9,304,082)	(18,481,244)	(19,050,121)	(30,591,899)
Other income (loss):
Interest income	90,849	65,436	151,392	127,174
Interest expense	(848,395)	(741,346)	(2,171,110)	(1,158,148)
Other income (loss), net	7,276	(798)	3,504	6,081
Gain (loss) on warrant derivative liabilities	(4,303,945)	877,729	(4,336,066)	693,457
Net loss	$ (14,358,297)	$ (18,280,223)	$ (25,402,401)	$ (30,923,335)
Basic and diluted net loss per share (in dollars per share)	$ (0.10)	$ (0.27)	$ (0.20)	$ (0.46)
Basic and diluted weighted-average shares outstanding (in shares)	139,070,329	67,398,837	126,394,244	66,893,846

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (25,402,401)	$ (30,923,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	348,843	213,964
Stock-based compensation expense	1,731,484	4,364,886
Fair value adjustment on warrant liabilities	4,336,066	(693,457)
Non-cash litigation settlement due in common stock	0	700,000
Amortization of loan cost and discount	975,743	208,148
Loss on retirement of fixed assets	421,843	3,388
Changes in assets and liabilities:
Receivables	136,072	4,368,773
Interest receivable	0	28,130
Prepaid expenses and other current assets	1,662,994	1,432,127
Accounts payable	673,635	(844,373)
Accrued expenses and other current liabilities	(1,026,781)	(4,297,864)
Net cash used in operating activities	(16,142,502)	(25,439,613)
Cash flows from investing activities:
Proceeds from the sale of short-term investments	0	35,035,420
Purchases of equipment and furnishings	(134,598)	(660,758)
Net cash provided by (used in) investing activities	(134,598)	34,374,662
Cash flows from financing activities:
Proceeds from public offering	13,951,218	0
Proceeds from term loan, net	0	24,012,078
Payment of principal on term loan	(2,427,362)	0
Net proceeds from exercise of warrants and stock options	2,766,605	704,700
Net cash provided by financing activities	14,290,461	24,716,778
Net increase (decrease) in cash and cash equivalents	(1,986,639)	33,651,827
Cash and cash equivalents at beginning of period	56,959,485	22,261,372
Cash and cash equivalents at end of period	54,972,846	55,913,199
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	1,212,219	752,083
Cash paid for income taxes	800	800
Supplemental disclosure of non-cash activities:
Warrant liability exercise	1,558,377	0
Preferred stock conversion	7,400	0
Warrants issued in connection with term loan	0	633,749
Equipment and furnishings purchased on credit	0	79,247
Shares issued in connection with the class action settlement	$ 0	$ 4,500,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Description of Company and Basis of Presentation	6 Months Ended
Description of Company and Basis of Presentation	Jun. 30, 2017
Description of Company and Basis of Presentation [Abstract]
Description of Company and Basis of Presentation	1. Description of Company and Basis of Presentation CytRx Corporation ("we," "us," "our," CytRx" or the "company") is a biopharmaceutical company specializing in oncology. Our focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, our lead clinical candidate, has been tested in over 600 patients with various types of cancer. CytRx's lead product candidate is aldoxorubicin, a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor. Specifically, it is comprised of (6-maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Our lead indication for aldoxorubicin is for patients with advanced soft tissue sarcomas (STS). We met with the FDA in March 2017 to discuss a regulatory pathway for a New Drug Application (NDA) for aldoxorubicin in STS. Aldoxorubicin has received Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of STS. ODD provides several benefits including seven years of market exclusivity after approval, certain R&D related tax credits, and protocol assistance by the FDA. European regulators granted aldoxorubicin Orphan designation for STS which confers ten years of market exclusivity among other benefits. On July 27, 2017, CytRx entered into an exclusive worldwide license with NantCell, Inc. ("NantCell"), granting them rights to develop, manufacture and commercialize aldoxorubicin in all indications. As part of the license, NantCell made a strategic investment of $13 million in CytRx common stock $1.10 per share, a premium of 92% to the market price on that date. CytRx is entitled to receive up to $343 million in milestones related to regulatory approvals and commercial milestones. CytRx is entitled to receive ascending double-digit royalties for net sales for soft tissue sarcomas and mid to high single digit royalties for other indications. NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin including the cost of filing the NDA. CytRx has an active drug discovery and research operation at our laboratory facilities in Freiburg, Germany, focusing on the creation of novel drug anti-cancer candidates by combining our proprietary linker technologies with ultra-high potency cytotoxic drugs. We are expanding our pipeline of ultra-high potency oncology candidates through our LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and next generation linker technologies for the development of a new class of potential breakthrough anti-cancer therapies. We have created a "toolbox" of linker technologies that have the ability to significantly increase the therapeutic index of ultra-high potency drugs (10-1,000 times more potent than traditional chemotherapies) by controlling the release of the drug payloads and improving drug-like properties. After infusion, these ultra-high potency drug conjugates bind to circulating albumin for transport of the drug to the tumor. Subsequently, due to specific conditions within the tumor, the linkers are cleaved and release the anti-cancer drug payload. Our current efforts are focused on two classes of ultra-high potency drug conjugates. Our strategy across these programs is to generate additional pre-clinical data that will allow us to make informed decisions regarding the selection of one or both programs for moving into human clinical trials either independently or on a partnered basis. The accompanying condensed financial statements at June 30, 2017 and for the three-month and six-month periods ended June 30, 2017 and 2016, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2016 have been derived from the our audited financial statements as of that date. The financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company's audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2016. As a result of the worldwide license of all of our rights to aldoxorubicin to NantCell, NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin, thereby enabling us to eliminate our future research and development activities related to aldoxorubicin. Currently, our only research and development activities are conducted by our Freiburg, Germany, laboratory facility. For this reason and others, our operating expenses are expected to be significantly lower in the near future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Foreign Currency Remeasurement	6 Months Ended
Foreign Currency Remeasurement	Jun. 30, 2017
Foreign Currency Remeasurement [Abstract]
Foreign Currency Remeasurement	2. Foreign Currency Remeasurement The U.S. dollar has been determined to be the functional currency for the net assets of our German laboratory facilty. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a gain of approximately $6,200 and $1,300, respectively, for the three-month and six-month periods ended June 30, 2017 and a gain of approximately $600 and $5,800, respectively, for the three and six-month periods ended June 30, 2016, respectively. The Company does not engage in currency hedging transactions.

- Definition

The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.

+ References + Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	6 Months Ended
Recent Accounting Pronouncements	Jun. 30, 2017
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements In January 2017, the FASB issued updated guidance to clarify the definition of a business within the context of business combinations. The updated guidance requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This updated guidance is expected to reduce the number of transactions that need to be further evaluated as business combinations. If further evaluation is necessary, the updated guidance will require that a business set include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output. The updated guidance will remove the evaluation of whether a market participant could replace missing elements. The new guidance is effective for annual and interim periods beginning after December 15, 2017 and is to be applied on a prospective basis. We are currently evaluating the new guidance. In January 2017, the FASB issued updated guidance which eliminated Step 2 from the goodwill impairment test. Step 2 is the process of measuring a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires entities to measure a goodwill impairment loss as the amount by which a reporting unit's carrying value exceeds its fair value, limited to the carrying amount of goodwill. The FASB also eliminated the requirements for entities that have reporting units with zero or negative carrying amounts to perform a qualitiative assessment for the goodwill impairment test. Instead, those entities would be required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount. The new guidance is effective for intrerim or annual goodwill impairment tests performed in fiscal years beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the new guidance. In March 2016, the FASB issued Accounting Standards Update 2016-09, Compensation—Stock Compensation ("ASU 2016-09"). ASU 2016-09 includes several areas of simplification to stock compensation including simplifications to the accounting for income taxes, classification of excess tax benefits on the Statement of Cash Flows and forfeitures. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016. We adopted this Standard on January 1, 2017. The adoption of this Standard did not have material impact to the Company's financial position or its results of operations. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 allows the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The Update 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and early adoption is permitted. We are still evaluating the effect of this update. In January 2016, the FASB issued Accounting Standards Update 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). ASU 2016-01 eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. The standard also clarifies the need to evaluate a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with our other deferred tax assets. The update 2016-01 is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Term Loan

6 Months Ended

Jun. 30, 2017

Term Loan [Abstract]

Term Loan

4. Term Loan

	June 30, 2017			December 31, 2016
Term Loan Principal – Current	$	7,737,492		$	6,214,057
Issuance Cost/Loan Discount – Current		(1,036,452	)		(732,401	)
Term Loan, Net – Current	$	6,701,040		$	5,481,656

Long Term Loan Principal	$	14,835,146		$	18,785,943
End Fee Payable		1,771,250			1,771,250
Long Term Loan Discount/Issuance Cost		(792,889	)		(2,072,683	)
Long Term Loan, Net	$	15,813,507		$	18,484,510

XML 21 R10.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share	6 Months Ended
Basic and Diluted Net Loss Per Common Share	Jun. 30, 2017
Basic and Diluted Net Loss Per Common Share [Abstract]
Basic and Diluted Net Loss Per Common Share	5. Basic and Diluted Net Loss Per Common Share Basic and diluted net loss per common share is computed based on the weighted-average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per common share where the effect would be anti-dilutive. Common share equivalents that could potentially dilute net loss per share in the future, and which were excluded from the computation of diluted loss per share, totaled 44.8 million shares for each of the three-month and six-month periods ended June 30, 2017, and 22.4 million shares for each of the three-month and six-month periods ended June 30, 2016.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Warrant Liabilities

6 Months Ended

Jun. 30, 2017

Warrant Liabilities [Abstract]

Warrant Liabilities

6. Warrant Liabilities

	Six Months Ended June 30,
	2017			2016

Risk-free interest rate		1.13	%		0.20	%
Expected dividend yield		0	%		0	%
Expected lives		0.79			0.09
Expected volatility		125.3	%		59.3	%
Warrants classified as liabilities (in shares)		24,110,577			6,371,854

On July 19, 2017, 6,340,148 warrants expired.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stock Based Compensation

6 Months Ended

Jun. 30, 2017

Stock Based Compensation [Abstract]

Stock Based Compensation

7. Stock Based Compensation

We follow ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.

For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50.

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Statements of Operations:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development — employee	$	278,533	$	507,195	$	631,616	$	988,006
General and administrative — employee		401,820		2,499,368		869,485		3,156,418
Total employee stock-based compensation	$	680,353	$	3,006,563	$	1,501,101	$	4,144,424

Research and development — non-employee	$	—	$	—	$	—	$	—
General and administrative — non-employee		36,578		32,506		65,237		220,462
Total non-employee stock-based compensation	$	36,578	$	32,506	$	65,237	$	220,462

The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	Six Months Ended June 30, 2017			Six Months Ended June 30, 2016
Risk-free interest rate		2.04	%		1.47	%
Expected volatility		85.5	%		76.3	%
Expected lives (years)		6			5 - 10
Expected dividend yield		0.00	%		0.00	%

	Six Months Ended June 30, 2017
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2017		16,879,770			600,000		17,479,770		$	2.37
Granted		10,000			—		10,000		$	0.41
Exercised, Forfeited or Expired		(646,847	)		—		(646,847	)	$	3.16
Outstanding at June 30, 2017		16,242,923			600,000		16,842,932		$	2.34
Options exercisable at June 30, 2017		11,655,168			600,000		12,255,168		$	2.75

The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2017:

Range of Exercise Prices		Total Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Total Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$	0.41 - $1.50		4,317,533		9.45	$	0.44		1,586,461		9.46	$	0.44
$	1.51 – $2.50		8,669,296		7.32	$	2.26		6,835,946		7.07	$	2.22
$	2.51 – $4.00		960,670		6.64	$	2.88		937,337		6.61	$	2.87
$	4.01 – $32.55		2,895,424		5.69	$	5.24		2,895,424		5.69	$	5.24
			16,842,923		7.55	$	2.34		12,255,168		7.02	$	2.75

There were 27,989,723 and 32,502,790 warrants outstanding at June 30, 2017 and December 31, 2016, respectively both at a weighted-average exercise price of $0.68.

Restricted Stock

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Fair Value Measurements [Abstract]

Fair Value Measurements

8. Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management's best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	53,485	$	—	$	—		$	53,485
Warrant liabilities		—		—		(6,567	)		(6,567	)

The following table summarizes fair value measurements by level at December 31, 2016 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	56,276	$	—	$	—		$	56,276
Warrant liabilities		—		—		(3,789	)		(3,789	)

We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Liquidity and Capital Resources	6 Months Ended
Liquidity and Capital Resources	Jun. 30, 2017
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	9. Liquidity and Capital Resources At June 30, 2017, we had cash and cash equivalents of approximately $55.0 million. On July 27, 2017, we entered into a global strategic licensing agreement with NantCell Inc ("NantCell") for the exclusive rights to develop, manufacture and commercialize aldoxorbuicin for all indications. Under the terms of this Agreement, NantCell made a strategic investment into our Company by purchasing $13 million of our common stock. Concurrently, we announced the signing of an amendment to the Loan Services Agreement with Hercules whereby we made an immediate principal repayment of $5 million, a further $5 million repayment by September 30, 2017, and an updated schedule of monthly instalments with a new Term Loan maturity date of August 1, 2018. Under the NantCell license, NantCell agreed to assume all future costs of developing and commercializing aldoxorubicin. Management believes that our current cash and cash equivalents, along with the net proceeds of the common stock purchase (See Note 13), will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2017 and the first seven months of 2018 of approximately $35.6 million, which includes approximately $4.7 million for our clinical programs for aldoxorubicin, approximately $3.7 million for the research and clinical development of novel anti-cancer drug candidates at our Freiburg operations, approximately $1.1 million for general operation of our clinical programs, approximately $9.4 million for other general and administrative expenses, and approximately $16.6 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. If our licensing partner obtains marketing approval and successfully commercializes aldoxorubicin, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible other strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Equity Transactions	6 Months Ended
Equity Transactions	Jun. 30, 2017
Equity Transactions [Abstract]
Equity Transactions	10. Equity Transactions In the first quarter of 2017, there were 3,108 shares of our outstanding Series B Convertible Preferred converted by the holders into 7.4 million shares of our common stock. In the second quarter of 2017, there were 4,404,494 shares of our common stock issued from the exercise of warrants. On May 2, 2017, we issued 30.0 million shares of our common stock in a public offering. As of June 30, 2017, we have reserved approximately 10.4 million of our authorized but unissued shares of common stock for future issuance pursuant to our employee stock option plans issued to employees and consultants.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2017
Income Taxes [Abstract]
Income Taxes	11. Income Taxes At December 31, 2016, we had federal and state net operating loss carryforwards as of $339.0 million and $224.0 million, respectively, available to offset against future taxable income, which expire in 2017 through 2036, of which $152.0 million and $145.0 million, respectively, are not subject to limitation under Section 382 of the Internal Revenue Code.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments and contingencies

6 Months Ended

Jun. 30, 2017

Commitments and contingencies [Abstract]

Commitments and contingencies

12. Commitments and contingencies

Commitments

·	commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);

·	a percentage of non-royalty sub-licensing income (as defined in the agreement); and

·	milestones of $1 million for each additional final marketing approval that we obtain.

Contingencies

XML 29 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On July 27, 2017, we entered into a global strategic license agreement (the "License Agreement") with NantCell, Inc. ("NantCell"), for providing NantCell the exclusive rights to develop and commercialize aldoxorubicin for all indications. Under the terms of the License Agreement, CytRx is entitled to receive up to $343 million in milestone payments related to regulatory approvals and commercial milestones for aldoxorubicin. In addition, CytRx will receive certain specified royalties for all other indications (our receipt of which would obligate us to make certain payments to KTB). NantCell will be responsible for all future development, manufacturing and commercialization expenses, other than royalties and milestones that may be owed by CytRx under its existing license agreements. In connection with the License Agreement, on July 27, 2017, CytRx (i) entered into a stock purchase agreement with NantCell in which NantCell purchased $13 million of CytRx common stock at $1.10 per share, a 92% premium to market on that date, and (ii) issued to NantCell a warrant to purchase up to 3 million shares of common stock at $1.10, expiring on January 27, 2019. On July 27, 2017, we entered into a First Amendment to Loan and Security Agreement with Hercules to amend our existing long-term loan facility (the "Loan Agreement") originally entered into on February 5, 2016. The amendment provides for our payment, on July 28, 2017, of $5.0 million in outstanding principal and unpaid interest due under the Loan Agreement, plus a $100,000 prepayment charge, and for our repayment, on or prior to September 30, 2017, of an additional $5.0 million outstanding principal and unpaid interest due under the Loan Agreement, plus an additional prepayment charge. We made the first $5 million payment on July 28, 2017. In connection with the Loan Agreement, in February 2016 we issued the lenders warrants to purchase an aggregate of up to approximately 630,000 shares of our common stock at an exercise price of $2.05 per share. Pursuant to the amendment, a portion of the warrants (representing 80% of the total number of shares issuable upon exercise of the warrants) was amended to change the exercise price of that portion of the warrants from $2.05 per share to a reduced amount, to be calculated based upon the 30-day volume-weighted average price of our common stock over the 30-day period beginning 15 days before the July 28, 2017 announcement of the NantCell license transaction.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Term Loan (Tables)

6 Months Ended

Jun. 30, 2017

Term Loan [Abstract]

Schedule of Term Loan

The loan and security agreement contains customary representations, warranties and covenants.

	June 30, 2017			December 31, 2016
Term Loan Principal – Current	$	7,737,492		$	6,214,057
Issuance Cost/Loan Discount – Current		(1,036,452	)		(732,401	)
Term Loan, Net – Current	$	6,701,040		$	5,481,656

Long Term Loan Principal	$	14,835,146		$	18,785,943
End Fee Payable		1,771,250			1,771,250
Long Term Loan Discount/Issuance Cost		(792,889	)		(2,072,683	)
Long Term Loan, Net	$	15,813,507		$	18,484,510

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Warrant Liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Warrant Liabilities [Abstract]

Schedule of Weighted-average Assumptions

The following reflects the weighted-average assumptions for each of the six-month periods indicated:

	Six Months Ended June 30,
	2017			2016

Risk-free interest rate		1.13	%		0.20	%
Expected dividend yield		0	%		0	%
Expected lives		0.79			0.09
Expected volatility		125.3	%		59.3	%
Warrants classified as liabilities (in shares)		24,110,577			6,371,854

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Stock Based Compensation [Abstract]

Schedule of Total Stock-Based Compensation Expense from Stock Options and Warrants

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Statements of Operations:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development — employee	$	278,533	$	507,195	$	631,616	$	988,006
General and administrative — employee		401,820		2,499,368		869,485		3,156,418
Total employee stock-based compensation	$	680,353	$	3,006,563	$	1,501,101	$	4,144,424

Research and development — non-employee	$	—	$	—	$	—	$	—
General and administrative — non-employee		36,578		32,506		65,237		220,462
Total non-employee stock-based compensation	$	36,578	$	32,506	$	65,237	$	220,462

Schedule of Share-based Payment Award, Fair Value of the Stock Options Granted, Assumptions

The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	Six Months Ended June 30, 2017			Six Months Ended June 30, 2016
Risk-free interest rate		2.04	%		1.47	%
Expected volatility		85.5	%		76.3	%
Expected lives (years)		6			5 - 10
Expected dividend yield		0.00	%		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity

Presented below is our stock option activity:

	Six Months Ended June 30, 2017
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2017		16,879,770			600,000		17,479,770		$	2.37
Granted		10,000			—		10,000		$	0.41
Exercised, Forfeited or Expired		(646,847	)		—		(646,847	)	$	3.16
Outstanding at June 30, 2017		16,242,923			600,000		16,842,932		$	2.34
Options exercisable at June 30, 2017		11,655,168			600,000		12,255,168		$	2.75

Schedule of Share-based Compensation, Summarizes Significant Ranges of Outstanding Stock Options

The following table summarizes significant ranges of outstanding stock options under our plans at June 30, 2017:

Range of Exercise Prices		Total Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Total Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$	0.41 - $1.50		4,317,533		9.45	$	0.44		1,586,461		9.46	$	0.44
$	1.51 – $2.50		8,669,296		7.32	$	2.26		6,835,946		7.07	$	2.22
$	2.51 – $4.00		960,670		6.64	$	2.88		937,337		6.61	$	2.87
$	4.01 – $32.55		2,895,424		5.69	$	5.24		2,895,424		5.69	$	5.24
			16,842,923		7.55	$	2.34		12,255,168		7.02	$	2.75

XML 33 R22.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Measurements [Abstract]

Fair Value Measurements by Level for Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes fair value measurements by level at June 30, 2017 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	53,485	$	—	$	—		$	53,485
Warrant liabilities		—		—		(6,567	)		(6,567	)

The following table summarizes fair value measurements by level at December 31, 2016 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	56,276	$	—	$	—		$	56,276
Warrant liabilities		—		—		(3,789	)		(3,789	)

XML 34 R23.htm IDEA: XBRL DOCUMENT

Description of Company and Basis of Presentation (Details) $ / shares in Units, $ in Millions		6 Months Ended
	Jul. 27, 2017 USD ($) $ / shares	Jun. 30, 2017 USD ($) Patient Class
Description of Company and Basis of Presentation [Abstract]
Number of patients tested for various types of cancer \| Patient		600
Number of years Orphan Drug Designation provides several benefits of market exclusivity after approval		7 years
Number of years soft tissue sarcomas confers market among other benefits		10 years
Subsequent Event [Line Items]
Number of classes of ultra-high potency drug conjugates \| Class		2
NantCell, Inc [Member]
Subsequent Event [Line Items]
Net proceeds received from the sale of common stock		$ 13.0
Subsequent Event [Member] \| NantCell, Inc [Member]
Subsequent Event [Line Items]
Net proceeds received from the sale of common stock	$ 13.0
Common stock, share price (in dollars per share) \| $ / shares	$ 1.10
Percentage of common stock premium at market price	92.00%
Subsequent Event [Member] \| NantCell, Inc [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Milestone payments entitled to receive under license agreement	$ 343.0

XML 35 R24.htm IDEA: XBRL DOCUMENT

Foreign Currency Remeasurement (Details) - USD ($)	3 Months Ended		6 Months Ended
Foreign Currency Remeasurement (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Foreign Currency Remeasurement [Abstract]
Gain on foreign currency translation adjustment	$ 6,200	$ 600	$ 1,300	$ 5,800

XML 36 R25.htm IDEA: XBRL DOCUMENT

Term Loan (Details) - USD ($)					2 Months Ended	3 Months Ended		6 Months Ended
Term Loan (Details) - USD ($)	Jul. 28, 2017	Jul. 27, 2017	Feb. 08, 2016	Feb. 05, 2016	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Amount received under initial loan agreement								$ 0	$ 24,012,078
Term Loan, Net - Current						$ 6,701,040		6,701,040		$ 5,481,656
Long Term Loan, Net						15,813,507		15,813,507		18,484,510
Debt instrument, repayment of principal and unpaid interest								2,427,362	0
Interest expense						848,395	$ 741,346	$ 2,171,110	$ 1,158,148
Warrants [Member]
Debt Instrument [Line Items]
Number of warrants issued (in shares)							500,000		500,000
Warrants exercise price (in dollars per share)							$ 1.74		$ 1.74
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member]
Debt Instrument [Line Items]
Amount received under initial loan agreement			$ 25,000,000
Debt instrument, interest rate				10.25%
Debt instrument, minimum cash balance required to be maintained				$ 10,000,000
Number of warrants issued (in shares)				630,000
Warrants exercise price (in dollars per share)				$ 2.05
Debt instrument, maturity date								Feb. 01, 2020
Term Loan Principal - Current						7,737,492		$ 7,737,492		6,214,057
Issuance Cost/Loan Discount - Current						(1,036,452)		(1,036,452)		(732,401)
Term Loan, Net - Current						6,701,040		6,701,040		5,481,656
Long Term Loan Principal						14,835,146		14,835,146		18,785,943
End Fee Payable						1,771,250		1,771,250		1,771,250
Long Term Loan Discount/Issuance Cost						(792,889)		(792,889)		(2,072,683)
Long Term Loan, Net						15,813,507		15,813,507		$ 18,484,510
Interest expense						848,395	$ 741,346	2,171,110	$ 1,158,148
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Debt instrument, repayment of principal and unpaid interest	$ 5,000,000	$ 5,000,000
Maturity date of amended loan servicing agreement	Aug. 01, 2018
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Scenario, Forecast [Member]
Debt Instrument [Line Items]
Debt instrument, repayment of principal and unpaid interest					$ 5,000,000
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Warrants [Member]
Debt Instrument [Line Items]
Number of warrants issued (in shares)				634,146
Warrants exercise price (in dollars per share)				$ 2.05
Fair value of warrants classified as equity warrants						$ 633,749		$ 633,749
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				6.00%

XML 37 R26.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Basic and Diluted Net Loss Per Common Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	44.8	22.4	44.8	22.4

XML 38 R27.htm IDEA: XBRL DOCUMENT

Warrant Liabilities (Details) - USD ($)		3 Months Ended		6 Months Ended
Warrant Liabilities (Details) - USD ($)	Jul. 19, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative [Line Items]
Gain (loss) on warrant derivative liabilities		$ (4,303,945)	$ 877,729	$ (4,336,066)	$ 693,457
Subsequent Event [Member]
Derivative [Line Items]
Warrants expired (in shares)	6,340,148
Warrants [Member]
Derivative [Line Items]
Gain (loss) on warrant derivative liabilities		$ (4,303,945)	$ 877,729	$ (4,336,066)	$ 693,457
Risk-free interest rate				1.13%	0.20%
Expected dividend yield				0.00%	0.00%
Expected lives				9 months 14 days	1 month 2 days
Expected volatility				125.30%	59.30%
Warrants classified as liabilities (in shares)		24,110,577	6,371,854	24,110,577	6,371,854

XML 39 R28.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Stock Based Compensation (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jun. 30, 2017
Employees and Directors [Member]
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Unrecognized compensation expense related to unvested stock options, granted						$ 2,400,000
Unrecognized compensation cost, recognized as expense over a weighted-average period			1 year 4 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares subject to stock options (in shares)	16,842,932		17,479,770		17,479,770	16,842,932
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Risk-free interest rate			2.04%	1.47%
Expected volatility			85.50%	76.30%
Expected lives			6 years
Expected dividend yield			0.00%	0.00%
Contractual term			10 years
Number of Options (Employees and Non-Employees) [Abstract]
Outstanding at beginning of period (in shares)			17,479,770
Granted (in shares)			10,000	425,000
Exercised, forfeited or expired (in shares)			(646,847)
Outstanding at end of period (in shares)	16,842,932		16,842,932		17,479,770
Options exercisable at end of period (in shares)	12,255,168		12,255,168
Weighted-Average Exercise Price Options [Abstract]
Outstanding at beginning of period (in dollars per share)			$ 2.37
Granted (in dollars per share)			0.41
Exercised, forfeited or expired (in dollars per share)			3.16
Outstanding at end of period (in dollars per share)	$ 2.34		2.34		$ 2.37
Options exercisable at end of period (in dollars per share)	$ 2.75		$ 2.75
Stock Options [Member] \| Minimum [Member]
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Expected lives				5 years
Stock Options [Member] \| Maximum [Member]
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Expected lives				10 years
Stock Options [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares subject to stock options (in shares)	16,242,923		16,879,770		16,879,770	16,242,923
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Estimated annualized forfeiture rate				10.00%
Number of Options (Employees and Non-Employees) [Abstract]
Outstanding at beginning of period (in shares)			16,879,770
Granted (in shares)			10,000
Exercised, forfeited or expired (in shares)			(646,847)
Outstanding at end of period (in shares)	16,242,923		16,242,923		16,879,770
Options exercisable at end of period (in shares)	11,655,168		11,655,168
Stock Options [Member] \| Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares subject to stock options (in shares)	600,000		600,000		600,000	600,000
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Estimated annualized forfeiture rate				0.00%
Number of Options (Employees and Non-Employees) [Abstract]
Outstanding at beginning of period (in shares)			600,000
Granted (in shares)			0
Exercised, forfeited or expired (in shares)			0
Outstanding at end of period (in shares)	600,000		600,000		600,000
Options exercisable at end of period (in shares)	600,000		600,000
Stock Options [Member] \| Senior Management [Member]
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Estimated annualized forfeiture rate				2.00%
Stock Options [Member] \| Directors [Member]
Share-based compensation arrangement by share-based payment award, fair value assumptions and methodology [Abstract]
Estimated annualized forfeiture rate				0.00%
Stock Options [Member] \| Former Executive [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense		$ 1,900,000
Restricted Stock [Member]
Restricted Stock [Abstract]
Restricted stock expense	$ 83,029	$ 0	$ 165,146	$ 0
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued (in shares)		500,000		500,000
Exercise price of warrants (in dollars per share)		$ 1.74		$ 1.74
2000 Long Term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date			Aug. 06, 2010
Share-based compensation, shares subject to stock options (in shares)	400,000		400,000			400,000
Share-based compensation, shares available for future grant (in shares)						0
Number of Options (Employees and Non-Employees) [Abstract]
Outstanding at end of period (in shares)	400,000		400,000
2008 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares subject to stock options (in shares)	16,400,000		16,400,000			16,400,000
Share-based compensation, shares available for future grant (in shares)						10,400,000
Number of Options (Employees and Non-Employees) [Abstract]
Outstanding at end of period (in shares)	16,400,000		16,400,000
2008 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, outstanding stock options (in shares)						2,500,000
2008 Stock Incentive Plan [Member] \| Restricted Stock [Member] \| Chairman and Chief Executive Officer [Member]
Restricted Stock [Abstract]
Share based compensation arranged by share based payment award restricted stock granted (in shares)					2,325,581
Vesting period					3 years
Share based compensation of fair value of the restricted stock on the grant					$ 1,000,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stock Based Compensation, Schedule of Employee and Non Employee Service Share Based Compensation (Details) - Stock Options and Warrants [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employees [Member]
Total stock-based compensation expense resulting from stock options and warrants [Abstract]
Allocated employee and non-employee stock-based compensation expense, Total	$ 680,353	$ 3,006,563	$ 1,501,101	$ 4,144,424
Non-Employees [Member]
Total stock-based compensation expense resulting from stock options and warrants [Abstract]
Allocated employee and non-employee stock-based compensation expense, Total	36,578	32,506	65,237	220,462
Research and Development Expense [Member] \| Employees [Member]
Total stock-based compensation expense resulting from stock options and warrants [Abstract]
Allocated employee and non-employee stock-based compensation expense, Total	278,533	507,195	631,616	988,006
Research and Development Expense [Member] \| Non-Employees [Member]
Total stock-based compensation expense resulting from stock options and warrants [Abstract]
Allocated employee and non-employee stock-based compensation expense, Total	0	0	0	0
General and Administrative Expense [Member] \| Employees [Member]
Total stock-based compensation expense resulting from stock options and warrants [Abstract]
Allocated employee and non-employee stock-based compensation expense, Total	401,820	2,499,368	869,485	3,156,418
General and Administrative Expense [Member] \| Non-Employees [Member]
Total stock-based compensation expense resulting from stock options and warrants [Abstract]
Allocated employee and non-employee stock-based compensation expense, Total	$ 36,578	$ 32,506	$ 65,237	$ 220,462

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stock Based Compensation, by Exercise Price Range (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares	Dec. 31, 2016 $ / shares shares
Stock Options [Member]
Share based compensation, shares authorized under significant ranges of outstanding stock option plans in period [Abstract]
Number of Options (in shares) \| shares	16,842,923
Weighted-Average Remaining Contractual Life	7 years 6 months 18 days
Weighted-Average Exercise Price (in dollars per share)	$ 2.34
Number of Options Exercisable (in shares) \| shares	12,255,168
Weighted-Average Remaining Contractual Life	7 years 7 days
Weighted-Average Exercise Price, Options Exercisable (in dollars per share)	$ 2.75
Aggregate intrinsic value of outstanding options \| $	$ 0.8
Aggregate intrinsic value of options vested \| $	$ 0.3
Closing price of the common stock (in dollars per share)	$ 0.63
Warrants [Member]
Share based compensation, shares authorized under significant ranges of outstanding stock option plans in period [Abstract]
Warrants outstanding (in shares) \| shares	27,989,723	32,502,790
Weighted-average exercise price of warrants outstanding (in dollars per share)	0.68	0.68
Range $0.41 - 1.50 [Member] \| Stock Options [Member]
Share based compensation, shares authorized under significant ranges of outstanding stock option plans in period [Abstract]
Range of Exercise Prices, Lower Range (in dollars per share)	$ 0.41
Range of Exercise Prices, Upper Range (in dollars per share)	$ 1.50
Number of Options (in shares) \| shares	4,317,533
Weighted-Average Remaining Contractual Life	9 years 5 months 12 days
Weighted-Average Exercise Price (in dollars per share)	$ 0.44
Number of Options Exercisable (in shares) \| shares	1,586,461
Weighted-Average Remaining Contractual Life	9 years 5 months 16 days
Weighted-Average Exercise Price, Options Exercisable (in dollars per share)	$ 0.44
Range $1.51 - 2.50 [Member] \| Stock Options [Member]
Share based compensation, shares authorized under significant ranges of outstanding stock option plans in period [Abstract]
Range of Exercise Prices, Lower Range (in dollars per share)	1.51
Range of Exercise Prices, Upper Range (in dollars per share)	$ 2.50
Number of Options (in shares) \| shares	8,669,296
Weighted-Average Remaining Contractual Life	7 years 3 months 25 days
Weighted-Average Exercise Price (in dollars per share)	$ 2.26
Number of Options Exercisable (in shares) \| shares	6,835,946
Weighted-Average Remaining Contractual Life	7 years 25 days
Weighted-Average Exercise Price, Options Exercisable (in dollars per share)	$ 2.22
Range $2.51 - 4.00 [Member] \| Stock Options [Member]
Share based compensation, shares authorized under significant ranges of outstanding stock option plans in period [Abstract]
Range of Exercise Prices, Lower Range (in dollars per share)	2.51
Range of Exercise Prices, Upper Range (in dollars per share)	$ 4.00
Number of Options (in shares) \| shares	960,670
Weighted-Average Remaining Contractual Life	6 years 7 months 20 days
Weighted-Average Exercise Price (in dollars per share)	$ 2.88
Number of Options Exercisable (in shares) \| shares	937,337
Weighted-Average Remaining Contractual Life	6 years 7 months 10 days
Weighted-Average Exercise Price, Options Exercisable (in dollars per share)	$ 2.87
Range $4.01 - 32.55 [Member] \| Stock Options [Member]
Share based compensation, shares authorized under significant ranges of outstanding stock option plans in period [Abstract]
Range of Exercise Prices, Lower Range (in dollars per share)	4.01
Range of Exercise Prices, Upper Range (in dollars per share)	$ 32.55
Number of Options (in shares) \| shares	2,895,424
Weighted-Average Remaining Contractual Life	5 years 8 months 8 days
Weighted-Average Exercise Price (in dollars per share)	$ 5.24
Number of Options Exercisable (in shares) \| shares	2,895,424
Weighted-Average Remaining Contractual Life	5 years 8 months 8 days
Weighted-Average Exercise Price, Options Exercisable (in dollars per share)	$ 5.24

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($) $ in Thousands	6 Months Ended
Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair value measurements by level for assets and liabilities measured at fair value on a recurring basis [Abstract]
Increase in fair value of warrant liabilities	$ 2,800
Recurring [Member]
Fair value measurements by level for assets and liabilities measured at fair value on a recurring basis [Abstract]
Cash equivalents	53,485	$ 56,276
Warrant liabilities	(6,567)	(3,789)
Level I [Member] \| Recurring [Member]
Fair value measurements by level for assets and liabilities measured at fair value on a recurring basis [Abstract]
Cash equivalents	53,485	56,276
Warrant liabilities	0	0
Level II [Member] \| Recurring [Member]
Fair value measurements by level for assets and liabilities measured at fair value on a recurring basis [Abstract]
Cash equivalents	0	0
Warrant liabilities	0	0
Level III [Member] \| Recurring [Member]
Fair value measurements by level for assets and liabilities measured at fair value on a recurring basis [Abstract]
Cash equivalents	0	0
Warrant liabilities	$ (6,567)	$ (3,789)

XML 43 R32.htm IDEA: XBRL DOCUMENT

Liquidity and Capital Resources (Details) - USD ($)			2 Months Ended	6 Months Ended
Liquidity and Capital Resources (Details) - USD ($)	Jul. 28, 2017	Jul. 27, 2017	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Estimated Projected Expenditure [Line Items]
Cash and cash equivalents				$ 54,972,846	$ 55,913,199	$ 56,959,485	$ 22,261,372
Debt instrument, repayment of principal and unpaid interest				2,427,362	$ 0
Currently projected expenditures for clinical programs				35,600,000
NantCell, Inc [Member]
Estimated Projected Expenditure [Line Items]
Purchase of common stock				$ 13,000,000
NantCell, Inc [Member] \| Subsequent Event [Member]
Estimated Projected Expenditure [Line Items]
Purchase of common stock		$ 13,000,000
Maturity date of amended loan servicing agreement		Aug. 01, 2018
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member]
Estimated Projected Expenditure [Line Items]
Maturity date of amended loan servicing agreement				Feb. 01, 2020
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Subsequent Event [Member]
Estimated Projected Expenditure [Line Items]
Debt instrument, repayment of principal and unpaid interest	$ 5,000,000	$ 5,000,000
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Scenario, Forecast [Member]
Estimated Projected Expenditure [Line Items]
Debt instrument, repayment of principal and unpaid interest			$ 5,000,000
Aldoxorubicin [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				$ 4,700,000
Other Programs [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				3,700,000
General Operation [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				1,100,000
Other General and Administrative Expenses [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				9,400,000
Interest and Term Loan Payment [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				$ 16,600,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details) - shares		3 Months Ended
Equity Transactions (Details) - shares	May 02, 2017	Jun. 30, 2017	Mar. 31, 2017
Class of Stock [Line Items]
Authorized but unissued shares of common stock (in shares)		10,400,000
Common stock shares issued from exercise of warrants (in shares)		4,404,494
Issuance of common stock (in shares)	30,000,000
Common Stock [Member]
Class of Stock [Line Items]
Number of preferred shares converted (in shares)			7,400,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of preferred shares converted (in shares)			3,108

XML 45 R34.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Millions	6 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Expiration date	Dec. 31, 2017
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Expiration date	Dec. 31, 2036
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 339.0
Federal [Member] \| Unrestricted [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		152.0
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		224.0
State [Member] \| Unrestricted [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 145.0

XML 46 R35.htm IDEA: XBRL DOCUMENT

Commitments and contingencies (Details) $ in Millions	6 Months Ended
Commitments and contingencies (Details) $ in Millions	Jun. 30, 2017 USD ($) Complaint
Loss Contingencies [Line Items]
Amount of milestone payment payable	$ 6.0
Potential future milestone payments on each additional final marketing approval	$ 1.0
Number of competing derivative complaints \| Complaint	2
Litigation settlement	$ 0.7
NantCell, Inc [Member]
Loss Contingencies [Line Items]
Purchase of common stock	13.0
Obligation payable	$ 0.6

XML 47 R36.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)			2 Months Ended	6 Months Ended
Subsequent Events (Details) - USD ($)	Jul. 28, 2017	Jul. 27, 2017	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Feb. 05, 2016
Subsequent Event [Line Items]
Debt instrument, repayment of principal and unpaid interest				$ 2,427,362	$ 0
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member]
Subsequent Event [Line Items]
Warrants to purchase shares of common stock (in shares)						630,000
Warrants exercise price (in dollars per share)						$ 2.05
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Debt instrument, repayment of principal and unpaid interest			$ 5,000,000
NantCell, Inc [Member]
Subsequent Event [Line Items]
Purchase of common stock				$ 13,000,000
Subsequent Event [Member] \| Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member]
Subsequent Event [Line Items]
Debt instrument, repayment of principal and unpaid interest	$ 5,000,000	$ 5,000,000
Prepayment charge	$ 100,000
Percentage of stock issuable upon exercise of the warrants		80.00%
Number of days to calculate volume-weighted average price of common stock		30 days
Subsequent Event [Member] \| NantCell, Inc [Member]
Subsequent Event [Line Items]
Warrants exercise price (in dollars per share)		$ 1.10
Purchase of common stock		$ 13,000,000
Common stock, share price (in dollars per share)		$ 1.10
Percentage of common stock premium at market price		92.00%
Subsequent Event [Member] \| NantCell, Inc [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Warrants to purchase shares of common stock (in shares)		3,000,000
Milestone payment received		$ 343,000,000

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

I>0I"G'X_OFW#-/B7^[8<1U1\K#> MY-$3SX+6=VPQSV:0<#AT49/0A8O)#(8O%"S]G95/'3L(-CD.^>J9WY(HSZ[Q/_91%N7X!J=/T087 MDZWL2STDW+(J<,_G7133Y_ .&>[=E]=%IWF1-S!NV8JT:I111G3K4:M6RM5SQ _/#/A8/E.. 1"#CT M(I65G4Z@&5&"V3D E_^,<@U+@,V V3)!3JK<$Y5$;E'5/GM@5W6+L^(=O]; MQ5&MX:A6<";F@X[VWB,B2-YXO00BCR?PU%;GJ]+#RMOV9$G_^0E MNKPO#])/'DY(EF?K)#R-LF+6OD]42[6JL9J4\EJZ B4KG8^E82U,;5J2[/F M-B9!0KF;Y3PU#4OAI0\\M@0,F5:9/?(:6NC0U\KK<@1.\BB,XGT>/=$>\F:? M\DFKLZ^;>!_B\ /]^"SH[//R/- ]+]"WWPW6!D#8KZL/8G!H7 M($H!&C0 "Z2,&!^5FU3**MMT02A,(88XWGN4)IC,0F7!M$.IRCC.<:["G^ MRKY?.#:!PITX1%LOJD&8[X0\N/(N%P^S# _3E"MGR0^'#3CB 6_+7,0<_&"XRKP=?;Y7PQJ^CE8U&YT4$9 MDB0RG<@TD %!<,\J:-=&X4"/9I%>?1=.D>$LO317674#8"N^M C>/?$ARH7V M_,"Z"N,J;,-BVE%;K&!<"!?)NB;#HP]0K$6O8:HE:(5L.UULAU09-FJBNN& MUYIWR2;W_3Z+$IQEISC;I-&.C5.LD_!]D$79Y?T5NP,X48O M;O'7_#TMR!\]C(TW4'ZN,08F\L'>I8,5XZ,+H:+72.KECP;?&2C5D'RS=# MN#+[L:V^+$GO]VD298_%#!S]1(]\ M?0_E_89J1POGJ-:X(=/JM$MN4PMM2MMY79#'V2,-->S_&!R>@IBMR5_G)T&: M/E,L_![$^\']S#8Z-8.-=";3U\ ++'?-':J):VIGQ60X8?F^=-Q(+\U0&U"0 M"776YZ:!>I>8QO[F0J-5@KFKKO]5=;6L7(, \TB!3!3D"+/S%^]14?K7#E5) MDN@.J\-4T!E8C^W!>I,':0X"UV,HN!YKX'J''Z$+5UY.Z ]GANTQ][E/<7& M09JGI9AFOZ>X^'^C]$>MJLR"9I.&"UV!CX1,LY/:\5YE9L7U%4/D'OPO+9 M]XB?+_:",B@-KK1$U]>W"=W%5O2L5WF?&=Y@HWAC'$-BNYUI\3]:6@?5COOS M&OJ5ZL(K:.=&MU4!@_O9$\X+ M/+GOX\N=VG-=9JO@N><-E H?6OYJJLZ$NP(3>N)_2Y'VL<(WY]]Q1N^M/[R M_C[:X/0CWM[AM$]3O61%3)7D5"K;8.23^M&23>-]NKDD0)A&Q337EP:U>H ME$>?"XV%)[U,JIU8UT^/87E#J=TMI=C41QDV>7]7VE7,TCRR_0Z>GC,/^U9 MR2[OF_TJ)T$6+=H9+HK/#XN[B!)\GN.MI)T7RW1;[[X, M3/CH6@7-GQ4.#(@NT%OQ1XRGQ=F/G]ECQ)\OG2$KJW'(._E7%YIRZ@B,C> MTKCOTO9RGVI$R8-)JBL05^6R'7$7[6K+@0..Z'Q9MXM]$TV[MV'BT7U$ MD\@@:U]$Z'ES)P$KCV35)I!>]72U#9( R]+$X\'@U.R#:+^0?ER 4%34PD MMC.%25>-3,>Z:0O34AHT+\4SCYJ67IU)VI7A5Y8WH6LK$5I6UH:U5W2G7W% MZ2;\%4:;7#]L$[]CDS:&%,;JH9';\-%:Z3SZKR),BR =;ME9'=52:$=$^N, MC[!&+"1Q'2MPWQ\;,^,P:=KY&RP8-#RZ%D0WO/S62^;._V..4J][14GAI!K-S!3\^-<:^,%_8&5RV=8L5F M6VOAL# .2@2B@GMQP,I.)P",,'LJ(:;'QOE&A;21T-,=]10:Q63/QNNE\"Z M+"><$>R+SEO)2VO>IIDW8"YY#3H0HG4SDJ\ON;VQ)-RHEL2024L/4YIP7'+. MWBA=F]00[%P^V\SL4_J>'+[V3O?3\50;XZR'(]XB;^\Y $$[%J%)#N(]I09U7\7,VT^;',65I9Q/#[#AG0 M$>VC7&#'!R3SX_S<[[25(YGD=00U5TI.&RW[3I"N,"%(365V:!K":D7&@K2!@QM.D/+];[_)&DT3_UW!AROC1EH3F2&/;4\& M;JRXTM,6\R6HA3SFC#25;P1UXZ&.XV2DC]]VSYP2'BHD^3QD"U 1S7U##H9 MOQ8X,&1$^\"E#@W^^T\__/33$=H%7IB,@?H^%]_.OCI)_Z_(4G^;W3TKS\? M'!W_CX.?_^,^]H 8.FQV[(\[;OLLVN709[JU8$@Y"YNK5F9PM\_1/BECMO<[G$;#3DQI>R1(6]F2A(3 M;,JQ! ]<-"MVWL%),&B82M7B0O@,55_ELE@;[AFXD%GC2=5T%Z MF=[D['ILWJI7=TC&TN=QK!YE&O !09#TJ^D)_+]RSP M(::P205.2M3EK!4[]:B#.;^@0DLY%.?1'D&2\(G3?1!?WL71 [_;8< CA4Q-(',9.8( MK-I2QF1ENL/FC(RO57S;]HJ/0=W\>+9IH2B<4W[W- (-X%O]2>W0 =F,4 M'D8!@W='ZF>H>?C2T2'M,XR%Q[Y?TC1L8OCN=AN[@MOOB9)D2#_:2F\DVT MU,E/YX;: VSB8>9,PQ@#&ZLK6LN875U2#EEM:K7%"62( #RD@:\4JOV.&;B M9T&Z97QQ%[^B)A,LQ8_KLG4?SR9.UV#UB/$VB/)Q0[4]!"HE#>TXOWI1D@ MJ25B]F7[^.Y=N$LLN@T@'S"+%QVQKGV4-6KC<]>]'5+LT7[.I]R2SA%-_E MYTF6IWNV.O5">G2ZEZY&B=7G M[^)?HM"F@=+FHF30[WK52+7(X&(?J\0N-!G&;4I5::YN<;I%%R18.,O551^Q M^M9#Y&OVS2EM>H)\R98>M9 0]V";=,1FW:'>8MN-0K'!O#=[:325$6_?G>, M6%Z.?4_VNW2;HELVRJG,?CH2PLRGE #->KA-=QE/V[QYMM-HK6XVCSC57]@D+Z$TM, RH7 MXA#%K$/&EFQ&&[[;YR'%F)GPB73"JI<2359)GU=>2$&EIVBBZPZ0J]F_'0 M.A)$[VT;;\'2)(I#@@D+3OM03.Y3<07:M"_8\S^6"?A>DO2//JG: 69C4H= MHTU4)O-)[\1!W#9VJJ:9H9E56Y+/' 8MD:7I9@$,,K[B^@S4:W>Y:.IM)CP" M1GISAQ!@/.JB\0#5PAR8ZS<#3&G;X :9R[87:?04L/LYF_;L.LK^6'^-AG/E M>M&Z?5")3N:AW#ALYUGK1\TZC?JJD>A,I3.!Q0>2#:J:V%=)GT]RK2Z/=-8] MH,^%=(6)5&) E@O E24#FVZHT3=OQHB+_FJ2F@@^+2215YP0^L(O+4/\A7CQ MB,26!_@6SQ\GPYP#35OV+'G!L_F\X5#C0Z._9@/%->/$+[:><".H!BV?LS_ M-22J+\P[V:^EBS,BZT[QA-@#U7O: J4CCHQM9)Y/D"ES.M"E;3;"0,K/[J9 MOP91!)5,?N4?N9 H5EX_Z6 88(?V"D29OF"QNED M.-)X_R&(JF-"@O#O^XP?+MY&YAN H[8A@,(CQ+(T S=6=]493-$8NIP,Q^-O MX;%;?Z[QN.2%<4UAJEWOM]2E\&IN$]%!8B(2!2/?T+B;=$3JQXQK$O5VDE^) M>'CMU%5"_FDKA(9DX9:8A+)K"]'GRC%&VI;>+6&^&%%D=[#J:3HF .E@
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